Transplantation of allogeneic pericytes improves myocardial vascularization and reduces interstitial fibrosis in a swine model of reperfused acute myocardial infarction by Alvino, Valeria Vincenza et al.
                          Alvino, V. V., Fernandez-Jimenez, R., Rodriguez-Arabaolaza, I., Slater, S.,
Mangialardi, G., Avolio, E., ... Madeddu, P. (2018). Transplantation of
allogeneic pericytes improves myocardial vascularization and reduces
interstitial fibrosis in a swine model of reperfused acute myocardial
infarction. Journal of the American Heart Association, 7(2), [e006727].
https://doi.org/10.1161/JAHA.117.006727
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1161/JAHA.117.006727
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via AHA at
http://jaha.ahajournals.org/content/7/2/e006727. Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Transplantation of Allogeneic Pericytes Improves Myocardial
Vascularization and Reduces Interstitial Fibrosis in a Swine
Model of Reperfused Acute Myocardial Infarction
Valeria Vincenza Alvino, MSc;* Rodrigo Fernandez-Jimenez, MD;* Iker Rodriguez-Arabaolaza, BSc;* Sadie Slater, PhD;
Giuseppe Mangialardi, MD; Elisa Avolio, PhD; Helen Spencer, PhD; Lucy Culliford, PhD; Sakinah Hassan, MRes; Lorena Sueiro Ballesteros,
MRes; Andrew Herman, PhD; Ali Ayaon-Albarran, MD; Carlos Galan-Arriola, DVM; Javier Sanchez-Gonzalez, PhD; Helena Hennessey, BSc;
Catherine Delmege FRCPath; Raimondo Ascione, MD; Costanza Emanueli, PhD; Gianni Davide Angelini, MD; Borja Ibanez, MD, PhD;
Paolo Madeddu, MD
Background-—Transplantation of adventitial pericytes (APCs) promotes cardiac repair in murine models of myocardial infarction.
The aim of present study was to conﬁrm the beneﬁt of APC therapy in a large animal model.
Methods and Results-—We performed a blind, randomized, placebo-controlled APC therapy trial in a swine model of reperfused
myocardial infarction. A ﬁrst study used humanAPCs (hAPCs) frompatients undergoing coronary artery bypass graft surgery. A second
study used allogeneic swine APCs (sAPCs). Primary end points were (1) ejection fraction as assessed by cardiac magnetic resonance
imaging and (2) myocardial vascularization and ﬁbrosis as determined by immunohistochemistry. Transplantation of hAPCs reduced
ﬁbrosis but failed to improve the other efﬁcacy end points. Incompatibility of the xenogeneic model was suggested by the occurrence
of a cytotoxic response following in vitro challenge of hAPCs with swine spleen lymphocytes and the failure to retrieve hAPCs in
transplanted hearts. We next considered sAPCs as an alternative. Flow cytometry, immunocytochemistry, and functional/cytotoxic
assays indicate that sAPCs are a surrogate of hAPCs. Transplantation of allogeneic sAPCs beneﬁted capillary density and ﬁbrosis but
did not improve cardiac magnetic resonance imaging indices of contractility. Transplanted cells were detected in the border zone.
Conclusions-—Immunologic barriers limit the applicability of a xenogeneic swine model to assess hAPC efﬁcacy. On the other
hand, we newly show that transplantation of allogeneic sAPCs is feasible, safe, and immunologically acceptable. The approach
induces proangiogenic and antiﬁbrotic beneﬁts, though these effects were not enough to result in functional improvements. ( J Am
Heart Assoc. 2018;7:e006727. DOI: 10.1161/JAHA.117.006727.)
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C oronary artery disease is the leading cause of deathworldwide, accounting for over 17 million deaths annu-
ally. Ischemic heart failure has reached epidemic proportions,
accounting for an estimated 26 million people worldwide and
resulting in more than 1 million hospital episodes annually in
the United States and Europe.1
Transplantation of proangiogenic cells following an acute
myocardial infarction (MI) may help prevent the infarct
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extension by promoting cardiomyocyte rescue, awakening the
hibernated myocardium in the area at risk, and modulating
inﬂammation and ﬁbrosis.2,3 Cell therapy of coronary artery
disease has evolved rapidly from bench to bedside; however,
despite positive results in murine models of MI, small- or
medium-sized clinical studies and meta-analyses have only
shown modest beneﬁt in humans.4–7 This could be principally
because of the use of inappropriate and ill-deﬁned cell
populations, which calls for a continued search for optimal,
quality-assured cell products. Moreover, very few studies have
adopted the robust approach to forecasting clinical efﬁcacy
through validation in both small and large animal MI models
before moving to humans.8
Different mesenchymal cell populations have been isolated
from the adventitial layer of murine and human vessels.9–15 In
a seminal study, we discovered the presence of CD133+/
CD34+/KDR+ cells endowed with potent vasculogenic activity
in the human fetal aorta.14 Searching for a similar angiogenic
cell population in the human adult vasculature, we have
focused on adventitial pericytes (APCs) that coexpress in situ
the classical markers NG2 and PDGFRb and the cell surface
glycoprotein CD34. Using a Good Manufacturing Practice–
compliant standard operating protocol (SOP), which consists
of an initial immunosorting for the CD34 antigen and
exclusion of CD31+ cells followed by adhesive culture/
expansion in a selective culture media, we were able to
expand millions of viable human APCs (hAPCs) from a small
remnant of the saphenous vein used for coronary artery
bypass graft surgery.
Expanded hAPCs share properties with mesenchymal stem
cells, including the expression of CD44, CD90, CD105, and
CD73, the lack of hematopoietic (CD45) and endothelial
markers (CD31, von Willebrand factor, and Vascular Endothe-
lial-cadherin), as well as clonogenicity, and immunomodula-
tory activity. In a series of studies conducted in mice, we
demonstrated that cell therapy with hAPCs has a remarkable
therapeutic potential for the treatment of peripheral and
myocardial ischemia.9,16–18 In particular, transplantation of
hAPCs promotes cardiac repair in immunodeﬁcient and
immunocompetent murine models of MI, through incorpora-
tion into the host’s vasculature and the release of angiocrine
and antiﬁbrotic factors.9,16,17 Haplotype analysis and cyto-
toxicity assays conﬁrmed tolerance of hAPCs by the mouse
immune system.16 We have also conducted comparative
studies in mice with MI, where hAPCs were shown to be
superior to cKit+ cardiac stem cells in terms of proangiogenic
activity. They also surpassed bone marrow–derived mesench-
ymal stromal cells in improving contractility indices and not
causing calciﬁcation, which was frequently observed in
mesenchymal stromal cells–transplanted hearts.9,16
In the attempt to make a further step towards clinical
translation, here we report the ﬁndings of the ﬁrst-ever large
animal trial of xenogeneic and allogeneic APC therapy in a
swine model of reperfused MI.
Materials and Methods
An extended version with details of experimental procedures
is provided in Data S1. The data, analytic methods, and study
materials will be made available upon request to other
researchers for purposes of reproducing the results or
replicating the procedure.
Ethics
Institutional Review Board approval was obtained according to
the guidelines noted in the Instructions to Authors. The
collection of long saphenous vein leftovers from coronary
artery bypass graft surgery complied with the principles
stated in the Declaration of Helsinki and was approved by the
Bath Research Ethics Committee (REC reference 06/Q2001/
197). Patients gave written informed consent for inclusion in
the study. Available clinical data of vein donors together with
speciﬁc use of corresponding hAPC lines are shown in
Table 1.
The in vivo studies on swine were conducted in accordance
with institutional guidelines and the Guide for the Care and
Use of Laboratory Animals (the Institute of Laboratory Animal
Clinical Perspective
What Is New?
• Pericytes are a promising cell product for cardiovascular
repair but experimental evidence of safety and efﬁcacy has
been obtained in murine models only.
• This is the ﬁrst cell therapy study of human and swine
pericytes in a large animal model of reperfused myocardial
infarction.
• Results show safety of the cell product. Pericyte transplan-
tation induces proangiogenic and antiﬁbrotic beneﬁts,
though these effects were not enough to result in functional
improvements as assessed by magnetic resonance imaging.
What Are the Clinical Implications?
• Triangulation of present data and previous studies in mice
suggest that pericyte therapy might be especially amenable
to patients with nonrevascularizable coronary artery disease
unresponsive to optimal treatment.
• Since pericytes improve angiogenesis and inhibit ﬁbrosis,
conjoint cardiomyogenic treatments may be necessary to
achieve full restoration of both perfusion and contractile
function.
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Resources, 1996). In particular, experimental protocols
received the approval of the UK Home Ofﬁce (licences 30/
3019 and I7A007F1C), the Centro National de Investigaciones
Cardiovasculares Carlos III (CNIC) Institutional Animal
Research Committee (CNIC 05/13), and the Regional Animal
Research Committee (PROEX 51/13). Also, the report of
research data from animal experiments follows the guidelines
of the ARRIVE (Animals in Research: Reporting In Vivo
Experiments) consensus document.19
APC Processing
Preparation of hAPCs
The Good Manufacturing Practice–compliant SOP for isola-
tion/expansion of hAPCs has been described previously.9 A
new investigation was conducted to verify the genetic stability
of expanded cell lines. To this aim, we performed (1)
chromosome analyses of G-banded metaphases in hAPCs at
the earliest possible passage (P2) and at P6/7 (which is the
expansion stage providing sufﬁcient cells for transplantation,
without causing replicative senescence)18 and (2) microarray
comparative genomic hybridization of DNA extracted from
vein tissue against DNA extracted from P7 hAPCs.
Preparation of sAPCs
Large-White swine (age 3–4 months) were terminally anes-
thetized for the collection of peripheral blood (through a
jugular vein cannula) and saphenous veins. The vein was
processed using a modiﬁcation of the hAPC-SOP, by growing
single cell suspensions of immunomagnetically sorted
CD31CD34+ cells onto culture dishes coated with 1%
porcine gelatin (Sigma-Aldrich, UK) containing Endothelial
Cell Growth medium-2 (Lonza, UK) supplemented with 10%
porcine serum. Adherent APC colonies appeared after 7 to
10 days of culture and were passaged to new culture dishes
once they reached 70% to 80% of conﬂuence. At P2, cells
were split for further expansion or generation of frozen
stocks. Peripheral blood was used to isolate mononuclear
cells by Istopaque-1077 solution (Sigma-Aldrich). These cells
were processed along with saphenous vein single cell
suspensions to verify the selectivity of the modiﬁed SOP.
The list of donor swine and speciﬁc use of corresponding
sAPC lines is provided in Table 2.
Assessment of sAPC Features
A series of comparative experiments was performed to assess
the purity of cells isolated from swine veins and to verify their
similarity to hAPCs. Cells were studied at P5/6, using 4
biological replicates (run in triplicate) unless otherwise
speciﬁed.
Antigenic characteristics
Immunoﬂuorescence microscopy and ﬂow cytometry analyses
were performed using the procedures and antibodies
described in Tables S1 and S2.
Analysis of gene expression
Semiquantitative polymerase chain reaction was performed
on cells cultured under normoxia (20% oxygen) or hypoxia (2%)
and their conditioned media (CM), using a Quant Studio 6 Flex
Real-Time Polymerase Chain Reaction system (Applied Biosys-
tems). The mRNA expression level was determined using the
2DCt method. The Taqman probes used in the molecular
biology studies are shown in Table S3.
Differentiation and clonogenic assays
Adipogenic and osteogenic differentiation studies were
conducted as previously described.9 In addition, single-cell
cloning was performed on 2 sAPC lines at P3, using a
motorized device connected to the ﬂow cytometric sorter
(Cyclone, Beckman Coulter). Sorted cells were placed into
each well of a 96-well culture plate (Greiner Bio-one, UK)
and cultured up to 4 weeks in endothelial cell growth
medium-2 for quantiﬁcation of colonies generated from a
single cell.
Analysis of vascular endothelial growth factor A
production
The levels of vascular endothelial growth factor A (VEGF-A)
protein were determined in CM by an anti-human ELISA kit
(R&D System, cat n#: DY293B). To this aim, sAPCs (N=3)
were cultured in a T25 ﬂask and exposed to normoxia or
hypoxia for 48 hours in 2.5-mL serum-free, endothelial basal
medium 2. In addition, a Western blot analysis was performed
to detect the same protein in concentrated CM and uncon-
ditioned media (endothelial cell growth medium-2).
Network formation
The capacity of forming networks on Matrigel was assessed
using sAPCs or swine pulmonary artery endothelial cells
(sPAECs) alone or both in coculture (N=3 biological replicates
run in triplicate). In addition, the network formation capacity
of sPAECs was assessed following stimulation with sAPC CM
or unconditioned media (endothelial cell growth medium-2).
Immunogenic Activity of APCs
Studies were carried out to compare the capacity of
xenogeneic hAPCs and allogeneic sAPCs (N=3 biological
replicates) to induce immune responses upon challenge with
swine spleen T lymphocytes.
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In Vivo Transplantation of APCs
Study design
Experiments were performed in a total of 42 female Large-
White swine.
A feasibility/efﬁcacy study was conducted in 32 swine
according to the protocol summarized in Figure 1A. In brief,
reperfused MI was induced at day 0 (vide infra). A cardiac
magnetic resonance (CMR) scan was performed 5 days after MI
induction, immediately before randomization to intramyocardial
injection of vehicle, hAPCs, or sAPCs. A follow-up CMR scan was
performed at 45 days. Immediately after the last CMR scan,
animalswere euthanized andmyocardial tissue samples from the
infarct, peri-infarct, and remote areas were collected for
histology, immunohistochemistry, andmolecular biology studies.
An additional study was conducted to assess the engraft-
ment of transplanted cells Figure 1B. Eight swine underwent
the MI protocol and were then randomized to receive an
intramyocardial injection of vehicle or hAPCs. Hearts were
collected from animals euthanized at day 10 post-MI (5 days
after vehicle or cell injection) for immunohistochemical
assessment of cells expressing the human nuclear antigen
and quantitation of human DNA using Alu Element-Based
Polymerase Chain Reaction.20 Human and swine GAPDH
primers were used as housekeeping genes. Additionally, DNA
from cultured hAPCs and swine vascular cells was used as
positive and negative controls, respectively.
In a separate experiment, 2 additional swine underwent the
sameMI protocol and then received an intramyocardial injection
of sAPCs, which were labeled 1 day in advance with the long-
term cell tracker CellTrackerTM CM-DiI (Life Technologies,
C700). Brieﬂy, CM-DiI was diluted 1:1000 in PBS and incubated
with conﬂuent cells (adherent to the culture plate) for 5 minutes
at 37°C and then at 4°C for an additional 15 minutes, in the
dark.Cellswere thenwashedwith PBS, fedwith freshmedia, and
placed in the incubator overnight until injection.
MI Procedure
The protocol to induce acute MI has been described
elsewhere.21,22 Brieﬂy, the left anterior descending coronary
artery, immediately distal to the origin of the ﬁrst diagonal
branch, was occluded for 50 minutes with an angioplasty
balloon introduced via the percutaneous femoral route using
Table 1. Clinical Characteristics of Human Donors and Speciﬁc Use of Corresponding hAPC Lines
Patient Code Age, y Sex
Risk Factors/Pathology/Intervention hAPC Line/Use
Smoker DM MI HPT HPC CPD CHF AF PCI Line Study
040613 B 72 M No No No Yes No No No No No 1 Efficacy
061213 D 78 F No No No Yes Yes Yes Yes No No 2 Efficacy
180314 D 78 M Ex No Yes Yes Yes No No Yes No 3 Efficacy
140414 A 66 F No No Yes Yes Yes No No No No 4 Cytotoxic assay
300414 F 57 M Yes No Yes Yes Yes No No No No 5 Efficacy
070514 A 72 M No No Yes Yes No No No No No 6 Efficacy
080514 C 71 M Ex No No Yes Yes No No No Yes 7 Efficacy
080514 D 84 M Yes No Yes Yes Yes Yes No No No 8 Efficacy
030614 E 66 M Yes No Yes No Yes No No No No 9 Cytotoxic assay
140115 B 66 M Ex Yes Yes Yes Yes No No Yes No 10 Engraftment
160115 A 54 F Yes No Yes Yes No No No No Yes 11 Engraftment
090215 A 72 M Ex No No Yes No No No Yes No 12 Engraftment
200215 B 67 F Yes No Yes Yes Yes No No No Yes 13 Engraftment
171115 A 67 M Yes No Yes No Yes No No No No 14 Karyotyping
171115 B 68 M No No Yes Yes Yes No No No No 15 Karyotyping
120116 A 80 M Ex Yes No Yes Yes No No No Yes 16 Karyotyping
120116 B 71 M No Yes Yes Yes Yes No Yes Yes No 17 Karyotyping
090216 B 73 M Ex No Yes Yes Yes No No No No 18 Karyotyping
APCs were isolated from saphenous vein leftovers of patients undergoing CABG surgery. Expanded hAPC lines (identiﬁed with a sequential numerical code from 1 to 18) were used for the
following studies: (1) Intramyocardial transplantation in swine with MI to assess feasibility/efﬁcacy of cell therapy; (2) Intramyocardial transplantation in swine with MI to assess
engraftment; (3) Assessment of genetic stability following in vitro expansion; and (4) Assessment of immunogenic activity. AF indicates atrial ﬁbrillation; CABG, coronary artery bypass
graft; CHF, congestive heart failure; CPD, chronic pulmonary disease; DM, diabetes mellitus; Ex, Ex-smoker (patient who stopped smoking at least 1 month before the surgery); hAPC,
human adventitial pericytes; HPC, hypercholesterolemia; HPT, hypertension; MI, myocardial infarction; PCI, percutaneous coronary intervention.
DOI: 10.1161/JAHA.117.006727 Journal of the American Heart Association 4
Adventitial Pericyte Therapy Alvino et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on January 26, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
the Seldinger technique. Balloon location and maintenance of
inﬂation were monitored angiographically. After balloon
deﬂation, a coronary angiogram was recorded to conﬁrm
patency of the coronary artery. A continuous infusion of
amiodarone (300 mg/h) was maintained during the proce-
dure in all swine to prevent malignant ventricular arrhythmias.
A biphasic deﬁbrillator was used to deliver nonsynchronized
shocks in case of ventricular ﬁbrillation occurrence.
CMR Protocol and Analysis
All CMR studies were performed with patients under anesthesia,
maintained by continuous intravenous infusion of midazolam, in
a 3-T Achieva Tx whole-body scanner (Philips Healthcare, Best,
The Netherlands) equipped with a 32-element phased-array
cardiac coil. The protocol included (1) a standard segmented cine
steady-state free-precession sequence to provide high-quality
anatomical references and to determine left ventricular end-
diastolic wall thickness (EDWT), left ventricular end-diastolic
volume (LVEDV), left ventricular end-systolic volume (LVESV),
and left ventricular ejection fraction (LVEF); (2) a late gadolinium-
enhanced sequence to assess infarct size; and (3) a dynamic
acquisition with dual-saturation technique during gadolinium-
based contrast administration to determine absolute myocardial
perfusion.23,24 CMR images were processed with a commercial
analysis software (QMassMR7.5Medis, Leiden, theNetherlands
and MR Extended Work Space 2.6, Philips Healthcare) and were
analyzed by 2 independent blinded experienced investigators as
previously described.23–25
APC Transplantation
The expansion of hAPC and sAPC lines in Bristol was
synchronized to the schedule for induction of MI in the
associate laboratory at the CNIC. Brieﬂy, APCs were expanded
to P6, seeded into multilayer ﬂasks (hyperﬂasks M Cell Culture
Vessel, Corning, Cat n#: 10030) allowing cell adhesion for
48 hours, and shipped by a certiﬁed courier to reach the CNIC
within 24 hours. On the injection day (day 5 post-MI), APCs
were detached by trypsinization and transplanted within 1 hour
from suspension in the vehicle, which consisted of endothelial
cell growth medium-2 media used to culture APCs. The choice
of injecting APCs at 5 days post-MI was guided by the
consideration that injected cells could perform better if not
directly exposed to an acute reperfusion injury.26 An aliquot of
the suspension was used to assess cell viability by the Trypan
Blue exclusion method. An expert cardiac surgeon, blind to the
treatment allocation, was responsible for injecting the vehicle
or cells in the LV peri-infarct zone via a left anterior minitho-
racotomy and direct vision, with animals under general
anesthesia. A total of N=10 micro-injections (for a total volume
3 mL) was performed in each animal.
The average injected dose of hAPCs was 21.49106 cells in
the efﬁcacy study (range 16–289106), and 10.39106 cells in
the engraftment study (range 8–129106). The dose admin-
istered in each single animal is illustrated in Table 3. The
efﬁcacy and engraftment studies using sAPCs used the ﬁxed
dose of 109106 cells (Table 4). The rationale for the variable
dose of hAPCs is that cell expansion from different veins yield
a different number of cells at P6/7, which is largely
dependent on the size of the vein leftover. In the case of
sAPCs, we used a dose similar to the median injected dose of
10 swine studies reported in a recent meta-analysis.8
Immediately after cell injection, the thoracotomy was
closed, and animals were extubated and sent to the recovery
room. During their recovery, animals were cared for by
dedicated veterinarians and technicians at the CNIC. All
animals enrolled in the efﬁcacy studies were returned to the
farm before ﬁnal follow-up CMR and euthanasia.
Histological and Immunohistochemistry of Swine
Hearts
After a general histological assessment to exclude the
presence of tumors or calciﬁcation, analyses of microvascular
density and ﬁbrosis in peri-infarct and remote zones were
Table 2. Code of Donor Swine and Speciﬁc Use of Corresponding sAPC Lines
Swine Code Line In Vitro Use In Vivo Use
020215 A 1 PCR, immunocytochemistry, Flow cytometry, differentiation, ELISA, WB Efficacy
190515 A 2 PCR, immunocytochemistry, Flow Cytometry, cell size, Matrigel, ELISA, immunogenic activity, WB Efficacy
190515 B 3 PCR, immunocytochemistry, Flow cytometry, cell size, Matrigel, ELISA, immunogenic activity, WB Efficacy/engraftment
150615 B 4 Immunocytochemistry, Flow cytometry
290715 A 5 PCR, immunocytochemistry, Flow cytometry, cell size, differentiation, Matrigel, ELISA, immunogenic activity Efficacy
220116 A 6 Differentiation, clonogenic assay
220116 B 7 Differentiation, clonogenic assay, ELISA
With swine under ketamine/midazolam, blood samples were collected through a cannula inserted into the jugular vein. Animals were then euthanized with Euthatal, and saphenous veins
were harvested for isolation and expansion of sAPCs. PCR, polymerase chain reaction; sAPC indicates swine adventitial pericytes; WB, Western blot.
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carried out by 2 examiners blind to the treatment allocation,
according to methods described previously.16,17 Quantitative
data from the 2 independent assessments were then
averaged and subjected to statistical analyses. Capillaries
and arterioles were calculated in 40 ﬁelds (at 9200
magniﬁcation) in different segments of the myocardium, and
the ﬁnal data were expressed as the number of capillaries or
arterioles per mm2.
Cardiomyocyte hypertrophy was evaluated by measuring
the cell cross-sectional area in both the ventricular border and
remote zones of animals, which received sAPCs or vehicle.
After performing antigen retrieval using Citrate Buffer
0.01 mol/L pH=6, for 30 minutes at 98°C, 5-lm-thick
sections were incubated with Alexa Fluor 488-conjugated
anti-Wheat Germ Agglutinin (Invitrogen, UK, 1:100, 30 min-
utes RT), followed by a mouse monoclonal anti-a-sarcomeric
actin primary antibody (Sigma, UK, 1:200, 2 hours 37°C) and
a TRITC-conjugated goat-anti mouse IgM secondary antibody
(Invitrogen, UK, 1:200, 1 hour Room temperature (RT)). Nuclei
were labeled with 40,6-diamidino-2-phenylindole. Sections
were analyzed at 9400 magniﬁcation. Images were taken in
1 or 2 sections per sample in areas in which cardiomyocytes
were transversally cut. For each sample, cross-sectional area
was measured in 100 cardiomyocytes, in which the nucleus
was centrally located within the cell.
Myocardial ﬁbrosis was analyzed by Azan-Mallory staining
followed by morphometric analysis using ImageJ software.16
The data were expressed as the percentage of the ﬁbrotic
area over the total myocardial area.
In the engraftment studies, the abundance of hAPCs in
the peri-infarct zone was assessed by immunostaining for
the human nuclear antigen. We included sections of human
hearts as a positive control to make sure the anti-human
antibody was working properly. Immunoﬂuorescence micro-
scopy was used to determine the persistence and location
of Dil-labeled sAPCs in different regions of swine hearts
5 days postinjection. In brief, 5-lm sections were cut and
antigen retrieval was performed after deparafﬁnization using
citrate buffer 0.02 mol/L, pH=6 for 30 minutes at 98°C.
Sections were incubated with anti-isolectin GS-IB4 (Vector,
UK, 1:200, overnight) followed by Alexa Flor 488 Strepta-
vidin secondary antibody (Invitrogen, UK, 1:200, 1 hour,
RT). Cardiomyocytes were stained with a mouse anti-a-
sarcomeric actin (Sigma, UK, 1:200, 2 hours, RT) followed
by Alexa Flor 649 anti-mouse secondary antibody (Invitro-
gen, UK, 1:200, 1 hour, RT). Nuclei were labeled with DAPI.
Figure 1. Study design. A, In the efﬁcacy study, swine were subjected to closed-chest 50-minute balloon
occlusion of the mid-LAD artery to induce acute MI. At day 5 post-MI, they underwent a comprehensive
basal CMR study. Animals that did not show a transmural infarction (at least 50% of the wall thickness
infarcted) were excluded. Immediately after day 5 CMR, animals were randomized to receive
intramyocardial vehicle or APC injection via minithoracotomy. CMR was repeated at day 45 post-MI and
hearts were harvested for histology and other tests described in the Materials and Methods section. B, A
similar protocol was used to assess cell engraftment with hearts being collected 5 days after vehicle or APC
injection. APC indicates adventitial pericyte; CMR, cardiac magnetic resonance; I/R, ischemia/reperfusion;
LAD, left anterior descending; MI, myocardial infarction.
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Sections were analyzed at 9200 magniﬁcation with a Zeiss
inverted microscope.
Morphometric analyses were performed using the free
software ImageJ (http://imagej.nih.gov/ij/).
Statistical Analysis
All results are presented as meanSE or range of sample
distribution. In some graphs, data are plotted as individual
values, with repeated-measures matched values connected by
a line. Gaussian distribution of quantitative values was
assessed using the D’Agostino-Pearson omnibus K2 test.
Two-group comparison analysis was performed by Student t
test or Mann–Whitney test if data were not normally
distributed. For comparison of multiple groups, ANOVA or
Kruskal–Wallis test was performed, followed by Holm-Sidak’s
or Dunn’s multiple comparisons test as appropriate. Correla-
tion between variables was calculated by regression analysis.
The contingency Fisher exact test was used to compare the
survival rate in the 2 treatment groups. Probability values (P)
<0.05 were considered signiﬁcant. Graphs were generated
using GraphPad Prism 6 (GraphPad Software, La Jolla, CA).
Table 3. Swine Allocation to Treatments and Dose of hAPC Lines in the In Vivo Studies
Swine ID Treatment hAPC Line No. Injected APCs Study Completion
Efficacy study
1900 1 1 289106 Completed
1901 0   Completed
1908 Not randomized   Died at d 1
2389 0   Completed
2395 0   Completed
2422 1 2 209106 Completed
2489 1 3 209106 Completed
2499 0   Completed
2569 0   Died at d 9
2575 1 5 209106 Completed
2578 1 5 169106 Completed
2620 1 6 239106 Completed
2625 Not randomized   Minor infarct at basal CMR
2626 0   Completed
2631 1 7+8 229106 Completed
2637 0   Completed
2644 0   Completed
2647 1 6 229106 Completed
2649 1 7+8 229106 Completed
Engraftment study
3265 0   Completed
3278 0   Completed
3280 1 10 89106 Completed
3288 1 11 119106 Completed
3382 0   Completed
3383 1 12+13 129106 Completed
3397 0   Completed
3400 0   Completed
Treatment 0, vehicle; Treatment 1, hAPCs (line identiﬁcation in Table 1). In the efﬁcacy study, 2 animals died before completion of the study: 1 before randomization and 1 in the control
group at day 9 post-MI. In the engraftment experiment, all animals completed the study and were euthanized at 10 days post-MI. CMR indicates cardiac magnetic resonance; hAPC, human
adventitial pericytes.
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Results
Antigenic Characteristics and Genetic Stability of
hAPCs
Using ﬂow cytometry and immunocytochemistry analyses, we
conﬁrmed the typical antigenic characteristics of hAPCs
reported previously.9,16,18 In addition, here we newly assessed
the genetic integrity of expanded hAPCs by conventional
karyotyping and comparative genomic hybridization arrays.
Two out of 5 hAPC lines did not divide in culture sufﬁciently to
allow chromosome analysis. In the remaining 3 lines studied,
karyotyping was successful at the expected quality standard
both at P2 and P6/7. Two of them showed no evidence of
genetic instability. The third cell line showed a balanced
rearrangement at P2 and an unrelated unbalanced rearrange-
ment at P7 (Figure S1). As the abnormality detected at P2 was
not seen at P7, these are likely to represent random genetic
changes occurring in culture, as seen not infrequently in
cultured ﬁbroblast cells. Consistently, the comparative
genomic hybridization array results were normal and showed
no evidence of the deletion detected at P7. The array quality
was lower than acceptable for diagnostic testing, which is
likely to be because of the quality of DNA extracted from the
poorly growing cultures. However, no evidence of copy
number change was detected in any region of the genome,
which would be considered pathogenic in a diagnostic setting.
These data provide reassurance about the biosafety of the
expanded human cell product.
Efﬁcacy Study With hAPCs
Clinical outcome
Closed-chest MI was performed in 19 female Large-White
swine. The dose of cells injected in each swine is reported in
Table 3. One swine was excluded from the study randomiza-
tion because of sudden death within 24 hours after ischemia/
reperfusion and another because the animal did not show
transmural infarction at day 5 CMR (<50% of wall thickness
was infarcted). The remaining 17 swine were randomized to
intramyocardial injection of vehicle (N=8) or hAPCs (N=9)
immediately after the CMR assessment at day 5 post-MI. In
the control group, 1 swine died 4 days after the injection of
vehicle. Thus, 16 swine (N=7 given vehicle and N=9 given
hAPCs) completed the study. The overall mortality rate for this
set of experiments was 11%. Contingency square analysis by
Fisher exact test indicates there was no difference between
the 2 groups regarding survival (2-tailed P=0.47). There was
no difference in body weight or hematocrit between groups at
day 5 and day 45 (Table 5). Likewise, there was no effect of
cell therapy on body weight gain from day 5 to day 45
(18.11.4 kg versus 18.61.4 kg in the vehicle group).
CMR outcome
Table 5 shows the relevant parameters that were measured at
day 5 post-MI (before injection of vehicle or hAPCs) and day
45 post-MI as well as the related absolute changes from day 5
to day 45. Representative CMR videos are reported as Videos
S1 through S4. Both groups were well balanced for basal
measurements, and there was no difference between treat-
ments at baseline and terminal assessment about the infarct
size (Figure 2A and 2B), LV volumes (Figure 2C and 2D), and
LVEF (Figure 2E) (all P>0.25). Likewise, no differences were
detected in perfusion at day 45 in all the evaluated segments
(Figure 2F, P>0.15). Representative images of CMR perfusion
maps are shown in Figure 2G.
Histological outcome
General examination excluded the occurrence of malignant
degeneration or calciﬁcation in hearts from the 2 treatment
groups. In addition, there was no difference between treat-
ments as far as the capillary or arteriole density end point is
concerned (P>0.20 for both comparisons, Figure 3A through
Table 4. Swine Allocation to Treatments and Dose of sAPC
Lines in the In Vivo Studies
Swine ID Treatment
sAPC
Line
No. of Injected
APCs
Study
Completion
Efficacy study
4117 0   Completed
4118 1 5 109106 Completed
4119 0   Completed
4125 1 2 109106 Completed
4126 1 3 109106 Completed
4146 0   Completed
4147 0   Completed
4162 0   Completed
4492 1 5 109106 Died at d 41
4493 1 3 109106 Completed
4503 1 2 109106 Completed
4507 1 1 109106 Died at d 5
4531 Not
randomized
  Died at d 3
Engraftment study
6075 1 3 109106 Completed
6080 1 3 109106 Completed
Treatment 0, Vehicle; Treatment 1, sAPCs (line identiﬁcation in Table 2). In the efﬁcacy
study, 3 animals died before completion: 1 before randomization and 2 in the cell
therapy group at day 5 (during immediate surgery recovery) and 41 post-MI. In the
engraftment experiment, all animals completed the study and were euthanized at
10 days post-MI. MI indicates myocardial infarction; sAPC, swine adventitial pericytes.
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3C). Importantly, hAPC therapy reduced interstitial ﬁbrosis in
the infarct border zone (19% compared with the vehicle,
P<0.01, Figure 3D and 3E), whereas the infarct scar was
unaffected.
Engraftment Study With hAPCs
Eight swine underwent the MI protocol and were randomized
5 days later to intramyocardial injection of vehicle (N=5) or
hAPCs (N=3). The dose of cells injected in each swine is
reported in Table 3. No casualties occurred in this set of
experiments. Immunohistochemistry studies of hearts col-
lected at day 10 post-MI did not detect human cells in any
treatment group. These data were validated and conﬁrmed by
real-time polymerase chain reaction–based quantitation of
human DNA. In parallel experiments, we could detect the
human-speciﬁc Alu sequence in the genomic DNA mixture
from hAPCs but not in the extracts of hAPC- or vehicle-
injected swine hearts. Results suggest a rapid clearance of
the injected xenogeneic cells, in contrast to the reportedly
long-lasting persistence of hAPCs following injection into
mouse infarcted hearts.16
Immunogenic Activity of hAPCs
Our previous work in mice suggests that hAPCs are immune
privileged, thereby enabling transplantation across major
histocompatibility barriers.16 Here, we veriﬁed this possibility
by assessing the humoral and cell-mediated immune
responses in swine. Results of 3 separate experiments
showed the absence of natural antibodies against hAPCs in
pre-immune porcine serum (Figure 4A through 4D). Addition-
ally, we could not observe any complement activation as
assessed by ELISA of complement component 3b (Figure 4E
and 4F) or complement-dependent cytotoxicity (caspase
activity, data not shown). However, hAPCs triggered a strong
immune reaction by swine splenocytes (Figure 4G and 4H). In
line, immunohistochemistry of swine hearts injected with
hAPCs showed a 2-fold higher inﬁltration of CD45/CD3
lymphocytes as compared with vehicle-injected hearts (data
not shown).
Isolation, Expansion, and Characterization of
sAPCs
Having demonstrated that the swine is not immune tolerant to
hAPCs and therefore not ideal for studying their therapeutic
activity, we next evaluated whether an equivalent cell product
could be obtained from swine saphenous veins. To this aim,
we adapted the SOP previously used for isolation/expansion
of hAPCs, with main modiﬁcations being the substitution of
fetal bovine serum with swine serum and use of swine gelatin
as a coating material of culture dishes. We expanded cells
from 7 swine veins for this study (with a success of 100%).
Table 5. CMR Parameters of the hAPC Efﬁcacy Study
Parameter
Control Group Cell Group
Day 5 Day 45 Delta Day 5 Day 45 Delta
BW, kg 32.61.4 51.22.3† 18.6 34.80.7 52.91.7† 18.1
Ht, % 30.40.6 31.60.6 1.2 29.21.1 31.20.5 2.0
LV mass, g/m2 80.95.6 78.4.2.7 2.5 85.94.2 84.52.2 1.4
Infarct size (% LV) 33.03.2 22.72.4† 10.3 33.32.9 23.4.2.6† 9.9
EDWT, infarct—mm 5.70.9 4.00.4† 1.7 6.00.9 4.40.8† 1.7
EDWT, remote—mm 4.50.8 5.90.6† 1.4 4.80.7 5.60.4† 0.8
LVEDV, mL/m2 157.35.1 179.68.9* 22.3 159.44.3 192.86.8† 33.4
LVESV, mL/m2 92.75.2 114.110.9 21.4 94.32.7 120.89.0* 26.5
LVEF, % 41.22.4 37.23.5 4.0 40.71.3 38.02.6 2.7
Infarct core perfusion, mL/100 g per min 95.921.7 87.217.5
Anterior border zone perfusion, mL/100 g per min 84.78.2 80.216.2
Inferior border zone perfusion, mL/100 g per min 109.26.5 101.59.7
Remote zone perfusion, mL/100 g per min 129.48.5 126.08.8
Data are presented as meanSE. N=7 and 9 swine in control and cell therapy group, respectively. CMR perfusion was not assessed in 1 swine in control and 1 swine in the cell group at
day 45 because of technical issues. Therefore, quantitative myocardial perfusion was assessed in 6 and 8 swine at day 45, respectively. BW indicates body weight; CMR, cardiac magnetic
resonance; EDWT, end-diastolic wall thickness; hAPCs, human adventitial pericytes; Ht, hematocrit; I/R, ischemia/reperfusion; LV, left ventricular; LVEDV, LV end diastolic volume; LVEF,
LV ejection fraction; LVESV, LV end-systolic volume.
*P<0.05 and †P<0.01 vs baseline (day 5 after I/R).
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Cells grew quickly in culture with an average doubling time of
2.5 days, reaching 30 million at P6 in 6 to 8 weeks. Both
saphenous vein–derived swine cells and hAPCs showed
similar spindle-shape morphology at contrast phase micro-
scopy (Figure 5A) and sizes as assessed by an image-based
cytometer (Figure 5B).
We next performed immunohistochemistry and ﬂow
cytometry studies to compare the 2 populations, using
validated species-speciﬁc antibodies as indicated in Tables
S1 and S2. The similarity of the 2 cell products was conﬁrmed
by immunocytochemistry analyses showing equivalent high
expression of the lineage antigens NG2, PDGFRb, and
vimentin (Figure 5C) and of the stemness markers GATA-4,
sex-determining region Y-box 2 (SOX-2), and octamer-binding
transcription factor 4 (Figure 5D). Both saphenous vein–
derived swine cells and hAPCs were negative for the
endothelial markers CD31 and VE-cadherin, and expressed
very low levels of CD146, whereas human umbilical vein
endothelial cells and sPAECs (positive controls) express all
the above antigens (Figure 5E). We also verify the expression
Figure 2. Cardiac parameters of individual animals measured by CMR at day 5 (prior injection of vehicle or hAPCs) and day 45 post-MI (end of
the study). A, Representative late gadolinium enhancement images at day 5 and day 45 post-MI in 2 swine injected with vehicle or hAPCs (donor
human cell line ID# 6). B through F, Plot individual data of infarct size (B), LVEDV (C), LVESV (D) both normalized for body surface area, LVEF (E),
and perfusion in the anterior and inferior border zones at day 45 post-MI (F). G, Representative myocardial perfusion maps at day 45 post-MI in 2
swine injected with vehicle or hAPCs (donor human cell line ID# 6). Perfusion maps were scaled between 0 and 200mL/100 g per min. *P<0.05
and **P<0.01 vs day 5. CMR indicates cardiac magnetic resonance; hAPCs, human adventitial pericytes; ID, identity number; LVEDV, left
ventricular end diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end systolic volume; MI, myocardial infarction.
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Figure 3. Immunohistochemistry analysis of hearts collected at day 45 post-MI from swine
injected with vehicle or hAPCs. A, Representative confocal images of capillaries and arterioles in
infarcted hearts injected with vehicle or hAPCs (donor human cell line ID# 6). Vessels are stained
with isolectin GS-IB4 (green) and a-SMA (red); cardiomyocytes are stained with a-sarc actin (white)
and nuclei with DAPI (blue); Inserts show a-SMA positive arterioles. Scale bar=100 lm. B and C,
Graphs show capillary density (B) and arteriole density data (C). Values were not normally
distributed. The bottom and top of the boxes represent the ﬁrst and third quartiles, while whiskers
indicate the 5 to 95 percentile. Median andmean values are represented as a horizontal line and “+”
symbol inside the boxes, respectively. D and E, Analysis of ﬁbrosis in the infarct border-zone.
Representative immunohistochemistry image of Azan-Mallory (total optical magniﬁcation9200) (D)
and graphs showing the quantiﬁcation of ﬁbrosis in hearts injected with vehicle or hAPCs (donor
human cell line ID#6). E, **P<0.01 vs vehicle group.a-SMA indicatesa-smoothmuscle actin;a-sarc
actin, a-sarcomeric actin; DAPI, 40,6-diamidino-2-phenylindole; hAPCs, human adventitial pericytes;
ID, identity number.
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of the T-box family transcription factor Tbx18, which is
reportedly selectively expressed by microvascular pericytes
and vascular smooth muscle cells in the adult mouse.27
Results conﬁrm that the TBX18 gene is detected by
polymerase chain reaction for both cell lines (Ct value
hAPCs=24.4 and Ct value sAPCs=26.6, data not shown),
with the expression being conﬁrmed at the protein level by
Western blot analyses of cell lysates (Figure 5F).
Furthermore, ﬂow cytometry studies indicate that, similar
to hAPCs, saphenous vein–derived swine cells abundantly
express the mesenchymal markers CD44, CD90, CD105, and
PDGFRb but are negative for CD146, CD31, and the
hematopoietic marker CD45 (Figure 6A through 6D). Swine
peripheral blood mononuclear cells and PAECs were used as
positive controls (Figure 6E and 6F). In addition, experiments
were conducted to exclude the possibility that contamination
of the vein extracts by circulating hematopoietic cells may
compromise the purity of the cell product. To this aim, we
isolated mononuclear cells from swine peripheral blood by
Histpaque-1077 solution and cultured them using the above-
described APC-SOP, with or without initial immune-magnetic
beads sorting for CD34/CD31. In both cases, no cell emerged
during a 1-month-long culture, thus providing a deﬁnitive
conﬁrmation that the adopted SOP is selective. Altogether
these data indicate that the expanded swine cell product is a
bona ﬁde equivalent of hAPCs.
Clonogenic and Differentiation Potential of sAPCs
Next, we attempted to conﬁrm the equivalence on functional
grounds. To investigate whether sAPCs can form clones, total
cells from 2 biological replicates were sorted as single cells
and cultured in 96-well plates. Two weeks later, 23% of cells
from 1 sAPC line formed colonies (57 out of 240), while the
other APC line gave rise to 67 colonies (27%). Of these
primary colonies, 9 and 14 could be further expanded in
culture.
We next exposed 3 sAPC lines to differentiation stimuli for
the derivation of mesenchymal lineages. All the lines showed
typical differentiation capacities, as denoted by the accumu-
lation of fat droplets and Oil-Red-O staining in the adipoge-
nesis assays and Alizarin Red and Alkaline phosphatase
staining in the osteogenesis assays (Figure S2). These results
denote similarities with the reported clonogenic activity and
in vitro differentiation properties of hAPCs.9
Proangiogenic Activity of sAPCs
One important feature of hAPCs consists of their ability to
modulate angiogenesis via direct contacts with, and transfer
of paracrine growth factors and microRNAs to endothelial
cells.9,16,28 Therefore, we next investigated whether sAPCs
share similar properties by testing their capacity to promote
endothelial cell network formation in a Matrigel assay.
Interestingly, preliminary experiments showed that the
sAPC-CM potentiates the network-forming capacity of human
umbilical vein endothelial cells, whereas the direct contact of
sAPCs and human umbilical vein endothelial cells in coculture
inhibits the network formation (data not shown). This
suggests that the physical interaction between cocultured
xenogeneic cells can override the proangiogenic activity of the
sAPC secretome. To exclude any species-speciﬁc incompat-
ibility that may confound the interpretation of results, we next
used swine endothelial cells (ie, sPAECs) as an angiogenic
target for sAPCs. In this setup, both sAPCs (Figure 7A) and
their CM (Figure 7B) led to potentiation of the network-
forming capacity of sPAECs. Moreover, the sAPC secretome
exhibited superior proangiogenic activity as compared with
the hAPC secretome (Figure 7B), with this difference being
compatible with a higher speciﬁcity of the sAPC-derived
paracrine factors for sPAECs.
Angiocrine Properties of sAPCs
Our previous studies showed that hAPCs express and secrete
a spectrum of angiogenic factors and microRNAs.9,16,17
Likewise, as shown in Figure 7C and 7D, sAPCs express
and secrete VEGF-A and the proangiogenic miR-132. They
also express the hypoxia-inducible miR-210, with levels being
increased in response to hypoxia (Figure 7C).
Immunogenic Activity of sAPCs
We performed a cytotoxic assay where sAPCs were chal-
lenged with interleukin-activated swine splenocytes. An initial
assay with cells in suspension showed no cytotoxic effect.
However, results were confounded by the sAPC tendency to
undergo spontaneous, time-dependent apoptosis (Figure S3).
Therefore, we repeated the assay with cells in adhesion.
Results conﬁrmed the compatibility between allogeneic sAPCs
and effector immune swine cells (Figure 8).
Efﬁcacy Study With sAPCs
Clinical outcome
Closed-chest reperfused MI was induced in 13 female Large-
White swine. Table 4 illustrates the attribution of swine to the
2 arms of the study, the cell line code and dose, and the study
outcome for each animal. One swine was excluded from the
study randomization because of sudden death at day 3 after
MI. The remaining 12 swine were randomized to intramyocar-
dial injection of vehicle (N=5) or sAPCs (N=7) after the CMR
assessment at day 5 post-MI. In the sAPC group, 1 swine died
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within a few hours after cell transplantation and another one
at 1 week before the 45-day post-MI follow-up. Thus, 10
swine (N=5 given vehicle and N=5 given sAPCs) survived
completing the full protocol. The overall mortality rate for this
set of experiments was 23%. Contingency square analysis
indicates there was no difference between the 2 groups for
survival (P=0.46). Furthermore, the cumulative analysis of
survival in swine given cell therapy with hAPCs and sAPCs
(n=14 out of 16) or vehicle (n=12 out of 13) showed no
difference between groups (2-tailed P=1.00). There was no
difference in body weight or hematocrit between groups at
day 5 and day 45 (Table 6). Likewise, there was no effect of
Figure 4. Assessment of swine immune response to hAPC. A through F, Humoral immune response to hAPCs. hAPCs were incubated with swine
or human serum (negative control) at different dilutions. There was no difference in the binding of anti-swine IgM or IgG antibodies on hAPCs when
incubated with human serum (A and C) or swine serum (B and D). Similarly, no difference was observed with regard to the levels of C3b, a metabolite
of complement cascade (E and F). Data are expressed as meanSEM; N=3 biological replicates. G and H, Cytotoxic activity of swine splenocytes on
hAPCs. To investigate cell-mediated immune response, hAPCs (target cells) were incubated with interleukin-activated swine splenocytes (effector
cells). G, Representative ﬂow cytometry graphs of hAPCs challenged with increasing concentrations of swine splenocytes. Values in each quadrant
represent the percent of total cells. H, Bar graphs show the percent of necrotic (Annexin V/P.I.+), late apoptotic (Annexin V+/P.I.+), early apoptotic
(Annexin V+/P.I.), and viable (Annexin V/P.I.) hAPCs. Data are expressed as meanSEM; N=2 biological replicates; *P<0.05 vs the “0:1” group.
A.U. indicates Arbitrary Units; FITC, Fluorescein isothiocyanate; hAPCs, human adventitial pericytes; P.I., propidium iodide.
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Figure 5. Comparison of APCs isolated fromhuman and swine saphenous veins. A, Upper panels: phase
contrast microscopy images of human and swine cells displaying similar spindle-shape features
(magniﬁcation 9100). Lower panels: Cells shown in the contrast-phase microscopy images are stained
with swine and human PE CD105 antibodies (PE=red laser) for measurement of cell size by Tali Image-
based cytometer (magniﬁcation940). B, Cell size histograms calculated by Tali andNovocyte 3000 (Acea,
Biosciences, Inc). The X axis in the left panels represents the cell size and the Y axis represents the number
of cells counted (3 cell lines for each group). The bar graph shows the mean and SEM, which was similar
between groups, though the rangeof cell sizewaswider for hAPCs. C, Representative immunoﬂuorescence
microscopy images show both hAPCs and sAPCs express the typical mesenchymal markers NG2, PDGFR-
b, and Vimentin. Values in each panel represent the meanSEM of 4 biological replicates. D,
Immunoﬂuorescence microscopy images show the expression of cardiac transcriptional factor GATA-4,
and the stemness markers OCT-4 and SOX-2. Blue ﬂuorescence of DAPI recognizes nuclei. Magniﬁcation
9200 and9400 (50-lm scale bar). E, Representative immunoﬂuorescence microscopy images of hAPCs
and sAPCs conﬁrming these cells do not express endothelial antigens, at variancewithHUVECs andPAECs
(positive controls). F, Western blot image showing Tbx18 protein corresponding to the 65 kDaMWwithin
human and swine APC lysate. APCs indicates adventitial pericytes; DAPI, 40,6-diamidino-2-phenylindole;
GATA-4, GATA binding protein 4; hAPCs, human adventitial pericytes; HUVECs, human umbilical vein
endothelial cells; MW, molecular weight; sPAECs, swine pulmonary artery endothelial cells; PDGFR-b,
platelet-derived growth factor receptor-b; OCT-4, octamer-binding transcription factor 4; sAPCs, swine
adventitial pericytes; SOX-2, sex determining region Y-box 2.
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sAPC therapy on body weight gain from day 5 to day 45
(11.51.8 kg versus 10.91.4 kg in the vehicle group).
CMR outcome
Similar to the human study, CMR assessment of the heart
structure and function showed no difference in groups
receiving sAPCs or vehicle (Figure 9, Table 6 and Videos S5
through S8).
Microvascular Outcomes of the Cell Therapy
Studies
General examination excluded the occurrence of malignant
degeneration or calciﬁcation in hearts from the 2 treatment
groups. We next investigated the effect of sAPC therapy on
microvascular and ﬁbrosis outcomes. The injection of sAPCs
increased the capillary density in the inferior segment of the
peri-infarct zone (51%, P=0.003 versus vehicle) and the
remote zone (34%, P=0.04 versus vehicle) (Figure 10A and
10B). Arteriole density was not affected in any of the
segments examined (Figure 10C).
Morphometric analysis of myocardial ﬁbrosis in the infarct
border zone indicates a beneﬁcial effect of sAPC therapy
(26% reduction versus vehicle, Figure 10D and 10E). The
amount of myocardial ﬁbrosis was inversely correlated with
capillary density in the whole population of injected swine
with vehicle or sAPCs (Figure 10F).
In addition, the assessment of cardiomyocyte remodeling
by calculation of the myocyte cross-sectional area denoted no
difference between groups (Figure 11).
Engraftment of sAPCs
Two swine underwent the MI protocol and were injected 5 days
later with sAPCs. The dose of cells injected in each swine is
reported in Table 4. No casualties occurred in this experiment.
Immunohistochemistry of hearts collected at 5 days post-
transplantation indicates the presence of DiI-labeled swine
cells in the infarct and peri-infarct border zone, with a few of
them surrounding the isolectin-positive vascular proﬁles and
others dispersed in the scar (Figure 12A). No signal from
injected swine cells was detected in the remote zone
(Figure 12B). As expected, controls hearts injected with vehicle
did not show any staining for the labeling tracer (Figure 12C).
There was no evidence for the differentiation of injected cells
into cardiomyocytes. The observed engraftment is in line with
Figure 5. Continued
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our previous study inmice, where Dil-labeled hAPCs were found
located in the infarct and infarct border zone.16
Discussion
Mounting evidence from qualitative and quantitative research
indicates that the triangulation of results from different
models, sources, and methodologies can help achieve a
deeper understanding of complex phenomena and synergize
the trustworthiness and translatability of a scientiﬁc
account.29,30 Nevertheless, neither the US Food and Drug
Administration nor the European Medicine Agency have yet
provided clear guidelines on whether cell therapy should be
tested in 1 or more animal species and, in the latter case, how
the nature and importance of data from different models
should be weighed before a clinical trial can begin. Further-
more, an interesting and yet unresolved controversy sur-
rounds the preclinical choice of using human cells, which
represent the ﬁnal therapeutic product but carry the problem
of being xenogeneic, or the corresponding animal products,
which may better simulate the current allogeneic/autologous
approach of clinical cell therapy.
In an attempt to resolve these fundamental issues, here, we
report the ﬁrst-ever study of human and swine APC therapy in
a large animal model of acute reperfused MI. The internal
validity of our investigation was ensured at several key levels,
with the randomized treatment groups being properly bal-
anced for basal measurements, receiving identical care and
Figure 6. Flow cytometry analyses of APCs isolated from human and swine saphenous veins. A and B, Representative ﬂow cytometry gating
procedure of hAPC line #1 and sAPC line #1 at P5. Total cell populations and the single cells (singlets) were gated according to FSC-A vs SSC-A
and FSC-A vs FSC-H parameters (i and ii). Viable cells were distinguished from dead cells using Fixable Viability Dye eFluor780 (iii) and further
gated for selected antigens (iv through xi and iv through xiii). Pericyte, mesenchymal, endothelial, and hematopoietic markers were studied. The
FMO control was used in the assessment and gating of CD146+ and PDGFRb+ cells, because of the use of multiple ﬂuorochromes (vii through ix
and viii through x). The same approach was used when studying the expression of CD45 and CD11b on sAPCs to exclude hematopoietic cell
contamination in the cell culture system (xi through xiii). Data were acquired using FACSCantoII (BD Biosciences) or Novocyte 3000 ﬂow
cytometer (ACEA Biosciences, San Diego, CA, USA) and analyzed using the FlowJo v10.3 software. C and D, Flow cytometry histograms for each
surface marker in representative hAPC (C) and sAPC lines (D). Negative control staining proﬁles are shown by the red histograms, whereas
speciﬁc antibody staining proﬁles are shown by light blue histograms. Bar graphs show the meanSEM values of 3 hAPC and sAPC lines. E and
F, Gating and histograms of fresh isolated swine PB-MNCs and swine PAEC line #1 at P5 used as positive control for the staining of
hematopoietic and endothelial markers, respectively. In both cell lines, the negative control staining proﬁle is shown by full red histogram, while
the positive staining proﬁle is shown by full light-blue histogram. FSC-A indicates Forward Scatter Area; FSC-H, Forward Scatter Height; FMO,
ﬂuorescence minus 1; hAPCs, human adventitial pericytes; PB-MNCs, Peripheral blood mononuclear cells; PDGFRb, platelet-derived growth
factor receptor-b; sAPCs, swine adventitial pericytes.
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assessment, and having similarly low levels of participant loss
at ﬁnal follow-up. Furthermore, we used the ARRIVE consensus
checklist to certify the proper and complete reporting of
research data.15 Results obtained in swine were critically
compared with previous studies conducted by us in mice
(Table 7), to draw more deﬁnitive conclusions about the safety
and efﬁcacy of this new cell therapy product.
Genomic stability has a crucial role in cell-based therapies.
Aneuploidy was observed in in vitro-cultured bone marrow-
derived mesenchymal stromal cells and adipose tissue–
derived mesenchymal stromal cells during culture expansion,
although cells with genomic alterations do not necessarily
undergo malignant transformation.31–33 By using both tradi-
tional karyotyping and array-based comparative genomic
hybridization, we demonstrate that hAPC expansion does
not result in signiﬁcant mutations within the genome, thus
providing novel reassurance on the safety of the cell product.
On the other hand, in vitro cytotoxicity experiments and
in vivo engraftment studies indicate rejection of hAPCs,
because of xenogeneic antigen recognition by swine T cells.
These new data contrast with the apparent tolerance of
hAPCs by the murine immune system.9,16 Although funda-
mental immunological mechanisms have strong similarities
among mammalians, environmental and pathogen pressure
Figure 6. Continued
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have led immune systems of swine and mice to markedly
diverge from each other, such that results obtained in 1
species are not always transferable to another.34 We
observed a second layer of species incompatibility when
performing coculture of sAPCs and human endothelial cells,
which unexpectedly resulted in inhibition of in vitro network
formation by the latter.
Because of the translational hurdles of the xenogeneic
strategy, we successfully adopted the alternative strategy of
obtaining pericytes from swine veins through a slightly
modiﬁed version of the human isolation protocol. The swine
cell product showed close similarities with hAPCs as assessed
by immunocytochemistry, ﬂow cytometry, and functional
assays. This proxy cell product represents an invaluable
material, considering the increasing popularity of swine as a
translational research model and potential cell/organ donor.
Importantly, the in vitro cytotoxicity assays and in vivo
engraftment studies showed that transplantation of allogeneic
sAPCs in the swine heart is feasible and immunologically
acceptable. Moreover, the safety of the proposed cell therapy
product was conﬁrmed by visual examination of animal
conditions and behavior and measurement of body weight,
hematocrit, and gross pathology of the heart. Quantiﬁcation
of cell engraftment by immunosorting, a method we
Figure 7. A, Representative phase-contrast and ﬂuorescent images of hAPCs (Ai), sAPCs (Aii), and sPAECs (Aiii) cultured alone or in
combination (Aiv, hAPCs+sPAECs; Av, sAPCs+sPAECs at a 1:4 ratio). APCs are stained with the long-term cell tracker Dil (red
ﬂuorescence). (Avi) Bar graph showing the fold increase in cumulative tube length induced by coculturing APCs with sPAECs in 2
separate experiments, each comprising 3 APC lines per group. Data are represented as meanSEM, *P<0.05 and **P<0.01 vs sPAECs.
B, Representative phase-contrast images of sPAEC networks formed on Matrigel in the presence of EGM2medium (Bi) or human (Bii) or
swine APC-CM (Biii-v, 3 cell lines). Magniﬁcation 910. (Bvi) Histograms summarize quantitative data of the tube length per ﬁeld in an
experiment comprising 3 APC lines per group). Data are represented as meanSEM, **P<0.01 and ***P<0.001 vs PAECs. +P<0.05 vs
hAPC-CM. C, Bar graphs shows the expression of VEGF-A (i), miR-210 (ii), and miR-132 (iii) in sAPC lysate under normoxia and following
stimulation by hypoxia. D, VEGF-A (i) and miR-132 (iii) were also found in conditioned media and increased following hypoxia. Western
blot image displaying secreted VEGF-A (MW=22 kDa) and also larger bands under normoxia condition (ii). The antibody detection of
these bands suggests that either multiple molecules are bound together in a multimerized complex or that VEGF-A is bound to another
molecule with the region bound by the antibody exposed/separate from the region bound by the corresponding molecule/receptor.
Values are meansSEM. **P<0.01 vs normoxia. CM indicates conditioned medium; Dil, 1,10-Dioctadecyl-3,3,30,30-Tetramethylindo-
carbocyanine; hAPCs, human adventitial pericytes; miR, microRNA; MW, molecular weight; sAPCs, swine adventitial pericytes; sPAECs,
swine pulmonary artery endothelial cells; VEGF-A, vascular endothelial growth factor A.
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Figure 7. Continued
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successfully adopted in mice,18 is challenging in large animals
such as swine, because of the difﬁculties in accurately
retrieving a relatively low number of injected cells from the
resident cell population, which is estimated to be in the range
of 10 billion cells. Imaging analyses have the potential to
provide semiquantitative information noninvasively, but avail-
able methods for assessing cell engraftment still have
limitations.35 In the present study, the presence of trans-
planted sAPCs was conﬁrmed by immunohistochemistry after
10 days postinfarction and 5 days from cell injection,
whereas the clinical beneﬁts were studied after 45 days.
Therefore, it is not possible to know how long the trans-
planted cells persisted in the myocardium. These aspects
represent a limitation of our investigation.
Table 6. CMR Parameters of the sAPC Therapy Study
Parameter
Control Group Cell Group
Day 5 Day 45 Delta Day 5 Day 45 Delta
BW, kg 35.12.0 46.01.5† 10.9 31.50.6 43.01.7† 11.5
Ht, % 28.70.7 31.50.7† 2.8 29.20.8 33.51.1* 4.2
LV mass, g/m2 78.14.7 83.64.9 5.5 73.23.2 81.56.3 8.3
Infarct size (% LV) 36.94.7 23.91.7* 13.0 35.12.9 24.3.2.6* 10.8
EDWT, infarct—mm 5.81.0 3.80.6† 2.0 4.90.5 4.00.8† 1.0
EDWT, remote—mm 4.20.3 5.30.8† 1.1 3.80.3 5.20.8† 1.4
LVEDV, mL/m2 155.88.6 188.013.5† 32.3 159.95.5 193.011.7* 33.1
LVESV, mL/m2 93.37.2 114.912.0* 21.6 99.66.9 124.114.1* 24.5
LVEF, % 40.32.3 39.52.7 0.8 37.92.8 36.44.1 1.5
Infarct core perfusion, mL/100 g per min 98.113.8 91.814.8
Ant border zone perfusion, mL/100 g per min 122.918.6 102.618.9
Inf border zone perfusion, mL/100 g per min 115.312.5 129.926.1
Remote zone perfusion, mL/100 g per min 118.29.8 116.422.7
Data are presented as meanSE. Ant indicates anterior; BW, body weight; CMR, cardiac magnetic resonance; EDWT, end-diastolic wall thickness; Ht, hematocrit; Inf, inferior; I/R,
ischemia/reperfusion; LV, left ventricular; LVEDV, LV end diastolic volume; LVEF, LV ejection fraction; LVESV, LV end-systolic volume; sAPCs, swine adventitial pericytes.
*P<0.05 and †P<0.01 vs baseline (day 5 after I/R). N=5 and 5 swine in control and cell therapy groups, respectively.
Figure 8. Cytotoxic assay of sAPCs and swine splenocytes. To investigate the cell-mediated immune response, sAPCs (target cells) were
incubated with interleukin-activated swine splenocytes (effector cells). A, Representative scattergram of sAPCs challenged with increasing
concentrations of swine splenocytes. Values in each quadrant represent the percent of total cells. B, Bar graph showing the percent of necrotic
(Annexin V/P.I.+), late apoptotic (Annexin V+/P.I.+), early apoptotic (Annexin V+/P.I.), and viable (Annexin V/P.I.) sAPCs. Data are
expressed as meanSEM; N=3 biological replicates. FITC indicates Fluorescein isothiocyanate; P.I., propidium iodide; sAPCs, swine adventitial
pericytes.
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With regard to efﬁcacy, the present study was consistent
with our previous publications showing a beneﬁt in microvas-
cular angiogenesis and interstitial ﬁbrosis.16,17 Neovascular-
ization and collagen deposition in the uninjured myocardium
are important determinants of the healing response to an
acute MI. Therefore, the ability of APCs to impact on these 2
parameters has considerable clinical value. When considering
underpinning mechanisms, the present study recapitulates
our previous results showing the APC inability to differentiate
into endothelial cell or cardiomyocyte lineages.18 Paracrine
mechanisms play a key role in the proangiogenic action of cell
therapy,36 and we previously demonstrated the validity of this
concept by gene silencing of angiogenic pathways in
pericytes.16,37 For instance, hAPCs express and release
proangiogenic and antiﬁbrotic factors, such as VEGF-A, leptin,
and miR-132, with the secretion of both being increased after
hypoxia.9,16,37 Western blot analysis showed that the VEGF-A
contained in the sAPC-CM corresponds to the mature 22-kDa
protein. This was also accompanied by larger VEGF-A bands.
The antibody detection of these bands suggests that multiple
molecules are bound together in a multimerized complex.
Alternatively, VEGF-A may be bound to another molecule,
such as secreted VEGF receptors, with the region bound by
the antibody exposed/separate from the region bound by the
corresponding molecule/receptor. Both possibilities are sup-
ported by published evidence.38,39
Figure 9. Cardiac parameters of individual animals measured with CMR at day 5 (prior injection of vehicle or sAPCs) and day 45 post-MI (end
of the study). A, Representative late gadolinium enhancement images at day 5 and day 45 post-MI in 2 pigs injected with vehicle or sAPCs
(donor swine cell line ID# 3). B through E, Plot individual data of infarct size (B), LVEDV (C), LVESV (D), and LVEF (E). F and G, Perfusion in the
anterior and inferior border zones at day 45 post-MI. Individual data (F) and representative myocardial perfusion maps at day 45 post-MI in 2
pigs injected with vehicle (ID# 4146) or sAPCs (ID# 4126) (G) Perfusion maps were scaled between 20 and 250 mL/min per 100 g. *P<0.05
and **P<0.01 vs day 5). CMR indicates cardiac magnetic resonance; ID, identity number; LVEDV, left ventricular end diastolic volume; LVEF, left
ventricular ejection fraction; LVESV, left ventricular end systolic volume; MI, myocardial infarction; sAPCs, swine adventitial pericytes.
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Swine and murine studies were also concordant in
excluding an effect of APCs on the infarct size as determined
by CMR and morphometry, respectively. On the other hand,
the present swine study does not replicate the positive
outcomes on cardiac function observed previously in
mice.16,17 Several factors may account for the discrepancy
in functional outcomes. An important difference between the
present investigation and studies in mice consists of the
infarction model (temporary versus permanent left anterior
descending occlusion). Furthermore, permanent left anterior
descending occlusion resulted in lower LVEF values in
mice16,17 as compared with the reperfused swine model
(20% versus 37%, respectively). The importance of baseline
LVEF in inﬂuencing the outcome of cell therapy remains
Figure 10. Beneﬁt of sAPC therapy on microvascular density and ﬁbrosis. A through C, Representative
images (scale bar=100 lm) (A) and bar graphs showing the effect of cell therapy with sAPCs on capillary (B)
and arteriole density (C). Representative images refers to hearts injected with vehicle or sAPCs (donor
swine cell line ID# 5). The inserts illustrate arterioles stained with a-SMA. Data are reported for 2 areas in
the border zone and the remote zone. D, Illustrative microscopy images (total optical magniﬁcation 9200)
and (E) bar graph illustrating the quantiﬁcation of the ﬁbrotic myocardium in the infarct border zone of
swine hearts injected with vehicle or sAPCs (donor swine cell line ID# 2). *P<0.05, **P<0.01, ***P<0.001
vs vehicle. F, Correlation of capillary density and myocardial ﬁbrosis in the whole population on swine
injected with vehicle (blue dots) or sAPCs (red dots). a-SMA indicates a-smooth muscle actin; ID, identity
number; sAPCs, swine adventitial pericytes.
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controversial. Two recent meta-analyses of bone marrow cell
therapy trials in patients with acute MI indicate that patients
experienced similar improvement in LVEF regardless of the
baseline LVEF. However, improvements in left ventricular end-
systolic volume were more pronounced in patients with lower
baseline LVEF.26,40 In contrast, in trials of chronic myocardial
ischemia, the increase in LVEF elicited by cell therapy was
signiﬁcant only in the group with lower LVEF at baseline.40
Therefore, the lack of contractility beneﬁt by APC therapy in
swine may be related to the mild impact of reperfused MI on
LVEF.
Another important difference of this large animal study
consists of having assessed functional outcomes at 1 single
follow-up time point. Sequential andmore prolonged evaluation
of cardiac function might help to interpret the discrepancies
between CRM and anatomical outcomes. For instance,
myocardial perfusion as determined by CMR was not improved
in the animals injected with sAPCs despite an increase of
capillary density observed in histology. We believe this might be
the consequence of several factors. Firstly, myocardial perfu-
sion, as well as other in vivo functional and hemodynamic
parameters, might be inﬂuenced by anesthesia with additional
potential inter- and intraindividual variations in experimental
models. Secondly, we did not perform pharmacological stress
tests, which might help to enhance the sensitivity of the
perfusion assessment. Thirdly, newly formed microvessels
might need a longer time to achieve optimal functional
capacity. An increase in capillaries rather than arterioles was
observed by histology. Arterioles are well known to be mainly
responsible for the regulation of tissue blood ﬂow; therefore it
might be the case that CMR was not able to detect subtle
changes inmyocardial perfusion. Finally, the beneﬁcial effect of
an enhanced capillary bed on cardiomyocyte survival may have
been blunted by microvascular vasoconstriction. Recent
investigation indicates that pericyte constriction contributes
to coronary no-reﬂow after postischemic reperfusion of the
cardiac microcirculation.41 It would be of paramount impor-
tance to investigate whether APC transplantation impacts on
postreperfusion microvascular constriction directly or through
paracrine mechanisms and if, conversely, pharmacological
control of coronary microvascular constriction may enhance
the restorative action of APC therapy.
Another key factor to consider is the cell dose and, with
regard to the hAPC transplantation study, the age of the cell
Figure 11. Morphometric evaluation of cardiomyocytes hypertrophy. A and B, CSA was measured in hearts of animals given vehicle or sAPC
therapy. Ai and Bi: Representative immunoﬂuorescence images of Wheat Germ Agglutinin (green), a-Sarc Actin (red), and DAPI (blue) in the
border and remote zones. Inserts show cell size at a higher magniﬁcation. Total optical magniﬁcation 9400. Aii and Bii: Histograms summarize
quantitative data of CSA. Data are presented as meanSEM. N=5 per each group. Difference between groups was measured by unpaired Mann–
Whitney test, and P value reported on the graphs. a-sarc actin indicates a-sarcomeric actin; CSA, cell cross-sectional area; DAPI, 40,6-diamidino-
2-phenylindole; sAPCs, swine adventitial pericytes.
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Figure 12. Engraftment of sAPCs in infarcted hearts. A, Representative immunoﬂuorescence images showing engraftment of sAPCs in the
infarct and nearby border zone (N=2). sAPCs are recognized by the red ﬂuorescence of the Vybrant Dil marker, which stains cell membranes. In
addition, a-Sarc Actin (white) identiﬁes cardiomyocytes. Isolectin B4 (green) has been used as a marker for endothelial cells, while DAPI (blue)
shows nuclei. sAPCs can be seen at a higher magniﬁcation in the inserts placed on the right of each image. B, Representative images showing
absence of sAPCs to the remote zone. C, Images taken from a vehicle-injected heart as a negative control for the Vybrant Dil staining. For all
images, total optical magniﬁcation is 9200. The scale bar in all images is 50 lm. a-sarc actin indicates a-sarcomeric actin; DAPI, 40,6-
diamidino-2-phenylindole; Dil, 1,10-Dioctadecyl-3,3,30,30-Tetramethylindocarbocyanine; sAPCs, swine adventitial pericytes.
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donors. A meta-analysis of 10 cell therapy studies in large
animal models reports a median injected dose (129106 cells),
which is similar to the doses used in our study.8 Our previous
investigation in mice included a dose titration experiment
showing that intramyocardial transplantation of 39105 hAPCs
is sufﬁcient to achieve signiﬁcant therapeutic effects.16 In
swine, we injected hAPCs and sAPCs at 53- to 93-fold (16–
289106) and 33-fold (109106) higher concentrations, respec-
tively. Since the swine heart is 1000 times heavier than the
mouse heart, these doses might be therapeutically suboptimal.
It should also be noted that despite injected doses of human
cells being greater than the dose elected for swine cell studies,
the latter exerted superior therapeutic effects. It is likely that
the majority of the human cells were lost because of the
immune response of the recipient. Additionally, they may have
caused other inadvertent adverse phenomena attributable to
their xenogeneic nature.
Aging causes a decline in the function and regenerative
capacity of human cells.42 Human donors of the present swine
study were older than those recruited in the mouse study
(733 years versus 576 years, respectively).17 Therefore,
the advanced age of the donors, in addition to the host reaction
to these cells, might have contributed to the failure of hAPCs to
exert the beneﬁts seen inmurine studies12,13 as well as in swine
studies where allogeneic sAPCs were sourced from young
donor animals.
Table 7. Comparison of 3 Blind, Randomized, Placebo-Controlled Studies Using APCs in Mice and Swine
Publication Reference (authors) Katare et al16 Avolio et al17 Current study
Transplanted cell type hAPCs hAPCs hAPCs and sAPCs
Human cell donor age, y Not reported 576 733*
Human cell donor sex (M/F) Not reported 8/1 6/1
Cell dose and route hAPCs: 39105 I.M.
hAPCs: 19106 I.M.
hAPCs:39105 I.M. hAPCs: 21.49106
(range 16–289106 I.M.
sAPCs: 109106 I.M.
Control for transplanted cells Vehicle and hMSCs Vehicle and hCSCs Vehicle
Recipient species Male immunodeficient
CD1-FOXOnu/nu
mice and immunocompetent
CD1 mice
Female immunodeficient
SCID mice
Female immunocompetent
Large-White swine
Interventional MI LAD permanent occlusion LAD permanent occlusion LAD artery temporary
occlusion/reperfusion
Group size (n/treatment group) 14 5 to 7 hAPCs study: 8–9
sAPC study: 5–7
Loss of participants at
final follow-up
14 out of 28 (50%)
Unbalanced between
treatments (vehicle: 9; APCs: 5)
End points evaluated
only at the final
follow-up assessment
hAPCs study: 1 out of 17 (5.8%)†
sAPCs study: 2 out of 12 (16.7%)*
Balanced (vehicle: 1; APCs: 2)
Outcomes
Safety Yes Yes Yes
LVEF (change vs vehicle) +8% in FOXnu/nu mice at 14 d
+15% in CD1 mice at 42 d
+29% in SCID mice at 14 d
+12% in SCID mice at 42 d
Not significant
Effect on infarct size Not determined Morphometry: Not significant
at 14 or 42 d
CMR: Not significant at 45 d
Effect on fibrosis in border zone Yes Yes hAPCs: yes
sAPCs: yes
Effect on capillary/arteriole
density
Yes Yes hAPCs: no
sAPCs: capillary density—yes
sAPCs: arteriole density—no
Effect on perfusion Yes Yes No
APC engraftment
(d postinjection)
hAPCs detected at 5 d in
border zone, at 14 d in infarct
hAPCs detected at 5 d in
border zone
hAPCs not detected at 5 d
sAPCs detected at 5 d in border-zone
CMR indicates cardiac magnetic resonance; hAPCs, human adventitial pericytes; hCSCs, human cardiac stem cells; hMSCs, human mesenchymal stromal cells; I.M., intramuscular; LAD,
left anterior descendent; LVEF, left ventricular ejection fraction; M/F, male/female; MI, myocardial infarction; sAPCs, swine adventitial pericytes.
*P<0.5 and †P<0.01 vs mouse study.
DOI: 10.1161/JAHA.117.006727 Journal of the American Heart Association 25
Adventitial Pericyte Therapy Alvino et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on January 26, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Conclusion
In summary, the results from this preclinical study support the
feasibility and safety of intramyocardially injected APCs for
the treatment of MI. The impact on efﬁcacy appears conﬁned
to an improvement of vascularization and reduction of
ﬁbrosis, which was still not enough to improve function and
contractile indices. When comparing this ﬁnding with the
previous observation that contractility is improved in mice
with nonreperfused acute MI,16 we speculate that APC
therapy might be especially amenable to patients with
nonrevascularizable coronary artery disease. The majority of
these patients have refractory angina, which is unresponsive
to optimal treatment and associated with a markedly impaired
quality of life.
Our proof of concept study was conducted to assess the
safety and therapeutic value of pericytes as a monotherapy. It
would be of paramount importance to test pericytes in
combination with optimal drug therapy for MI. Another attrac-
tive possibility is the association with other dedi-
cated approaches of regenerative medicine. Conjoint
cardiomyogenic treatments, for instance, using combinatory
transplantation of cardiac stem cells as shown by us previ-
ously17—exosomes and vesicles secreted by cardiac stem
cells43,44 or exogenous administration of selected mitosis-
related genes or microRNAs45–48—may result in synergistic
beneﬁt with the restoration of microvascular perfusion and
contractile function.
Finally, triangulation with data from our studies in mice
provides an invaluable method to interpret the experimental
results, but also calls for more standard reporting guidelines
for animal studies in cardiac regeneration.
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Data S1. 
 
Extended Materials and Methods 
Assessment of hAPC genetic stability   
The following whole genome analysis testing strategy was carried out on five cell lines and the 
source vein tissue:  
(i) Chromosome analysis of G-banded metaphases from the earliest possible passage (P2) and 
P7 cell cultures. This test detects both balanced and unbalanced chromosome rearrangements. 
Briefly, cultured cells were harvested using a robotic liquid handling system from Genial Genetic 
Solutions (Multiprep Genie 205), seeded on coverslips and fixed in Carnoy’s fixative. Metaphase 
chromosomes were G-banded using Trypsin and Leishman stain for karyotype analysis. Images 
of selected cells were captured using the MetaSystems cell finding and image analysis equipment 
and then karyotyped. Chromosome analysis was carried out to a quality standard QA4. According 
to the number of available metaphases, studies were performed on 10 or 20 cells. 
(ii) Microarray comparative genomic hybridization (CGH) of DNA extracted from vein tissue 
against DNA extracted from P7 cultured hAPCs. Pooled, sex-matched DNA was used as a 
control. GGH analysis detects acquired copy number changes present in a large proportion of 
cells. The assay was performed using the OGT 8x60K ISCA v2.0 array (Oxford Gene Technology, 
UK), which has an average resolution of 180kb. Data were analyzed with OGT CytoSure Interpret 
v4.7.   
APC immunogenic activity mediated by natural antibodies and complement 
Studies were carried out to verify the possibility that hAPCs trigger an immune response mediated 
by pre-existing xenoreactive antibodies and complement activation, which may contribute to 
immune rejection following transplantation in swine.  
We first determined if porcine serum contains natural antibodies that can recognize human 
antigens. To this aim, hAPCs were grown to confluence in a 96-well plate, fixed with 0.1% 
glutaraldehyde for 5min at +4° C and then blocked with PBS supplemented with BSA 1% for 
30min. After washing, cells were incubated for 1h at +37° C with undiluted or progressively diluted 
pre-immune porcine serum (Innovative Research, IPG-COMPL) or human serum as a negative 
control. Cells were washed three times with PBS and anti-porcine IgG or anti-porcine IgM were 
added to the wells for 2h at +37°C. After washing, p-nitrophenylphosphate (Sigma-Aldrich, 
AP0100) in diethanolamine was added to the wells as a substrate and after 5min plates were read 
at 405 nm. 
To assess complement activation, hAPCs were incubated with undiluted or serial dilutions 
of porcine pre-immune serum or human serum as a negative control for 1h at +37°C followed by 
incubation with complemented porcine serum for 1h at +37°C. The cells were washed three times 
with PBS, fixed with 0.1% glutaraldehyde for 5min at +4° C and then blocked with PBS 
supplemented with BSA 1% for 30min, washed twice again with PBS, and then blocked with 1% 
BSA. Complement activation was determined by measuring the deposition of C3b by ELISA 
(Antibodies-online, ABIN1560930), according to manufacturer’s instructions. 
APC immunogenic activity mediated by antigen-specific cytotoxic T-lymphocytes 
Isolation of effector cells 
Additional studies were performed to evaluate the possibility that xenogenic hAPCs or allogenic 
sAPCs may trigger an immune response by antigen-specific cytotoxic T-lymphocytes. To obtain 
effector cells, spleens were harvested from swine, minced in Petri dishes and crushed through a 
70µm cell strainer with the help of a 2mL syringe plunger. Strainers were washed five times with 
1x PBS (Life Technologies, 14190250) to release the splenocytes into the Petri dishes. The cell 
suspension was transferred into 50mL tubes containing 15mL of Histopaque-1077 (Sigma-
Aldrich, 10771) to separate the mononuclear fraction by gradient centrifugation (400xg for 30min 
at RT with no accelerator/brake). Cells were transferred into a new 50mL tube, washed with 30mL 
of 1x PBS and centrifuged at 400xg for 10min at RT. For erythrocytes exclusion, the resulting cell 
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pellet was resuspended in 1mL of 1x PBS and incubated in 5mL of 1x Red Blood Cells lysis buffer 
(BioLegend, 420301) for 10min at RT and protected from light. Then, cells were washed with 
30mL of 1x PBS and centrifuged at 400xg for 10min at RT. Live cells counting was performed 
using trypan blue exclusion. Then, 1x106 cells/mL were seeded in RPMI 1640 plus GlutaMAX 
medium (Life Technologies, 61870010) supplemented with 10% (v/v) heat-inactivated Fetal 
Bovine Serum (FBS) (Life Technologies, 10500064) 100 IU/mL penicillin and 0.1 mg/mL 
streptomycin (Life Technologies, 15070063). To stimulate Natural Killer lymphocytes (NK) as 
effector cells for the cytotoxic assay, the culture media was enriched with 100 IU/mL recombinant 
porcine interleukin-2 (R&D Systems, 652-P2) and 25 ng/mL recombinant porcine interleukin -12 
(R&D Systems, 912-PL) for 48h before the assay. 
Cytotoxic assay and flow cytometry analysis 
For the cytotoxic assay, splenocytes were challenged with hAPCs or sAPCs. Briefly, 5x105 target 
cells (hAPCs or sAPCs, three biological replicates) were seeded in 12 multi-well plates together 
with stimulated effector cells at four different target cell/effector cell ratios: 1:0, 1:1.5, 1:3 and 1:6. 
Target and effector cells were co-cultured in a humidified 5% CO2 incubator at +37°C for 4h in 
EGM-2. In a separate experiment, 3x105 sAPCs were seeded in 6 multi-well plates and let them 
attach for 48h. Then, stimulated effector cells were added to have the same ratio as above. 
Effector and target cells were co-cultured in a humidified 5% CO2 incubator at +37°C in EGM-2 
for 4h. 
For antibody staining, cell suspensions or trypsinized cells were transferred into 5mL 
polystyrene tubes (Corning, 352054) and centrifuged at 400xg for 10min at +4°C. Cell pellets 
were resuspended in 100 µL of FACS buffer (1% BSA (v/v) + 2mM EDTA in 1x PBS) and 
incubated with the early apoptotic marker FITC Annexin V (1:50, BD Pharmingen, 556419) for 
30min at +4°C. Propidium iodide (1:400, Invitrogen, P3566) was then added to cells. At least 
1x104 cells were acquired per sample with the same settings. Early and late apoptotic target cells 
were assessed measuring the percentage of Annexin V+/P.I.- and Annexin V+/P.I.+ respectively, 
using FlowJo software (FlowJo, LLD). Necrotic cells were identified as Annexin V-/P.I.+.The 
gating strategy included a step to distinguish effector and target cells using the major human 
histocompatibility antigen HLA (BioLegend, 311410) or labelling effector cells with a Violet Cell 
Tracer (Invitrogen, C34557). 
Flow cytometry 
To optimize the flow cytometry analysis and exclude the occurrence of hematopoietic cell 
contamination, we adopted a single-step staining - Fluorescence Minus One (FMO) protocol on 
three APC lines (the ones used for in vivo transplantation in the swine MI model, vide infra) and 
control swine MNCs. The FMO methodology is recommended in multiple fluorescence studies, 
like the one used here, to ensure that any spread of the fluorochromes into the channel of interest 
is properly identified. In addition, we used the Fixable Viability Dye eFluor 780 to label dead cells 
and exclude them from the gating strategy. The size of hAPCs and sAPCs was calculated using 
the Tali™ Image-based cytometer (Invitrogen) and Novocyte 3000 (Acea Biosciences). A total of 
2x105 cells were incubated with swine and human mesenchymal antibody, CD105 (LifeSpan), 
conjugated with phycoerythrin (PE), a bright and well-excited fluorophore once the laser light 
source passes through the cells. Also, CD105-PE ensures more specificity to the cell size 
measurement. Once stained, the cells were fixed with 1% (v/v) PFA in PBS. Unfixed and 
unstained cells were used to compare any cell size variation with fixed and stained cells. 
Semi-quantitative PCR on sAPCs  
Extracted total RNA (N=3 biological replicates) was reverse‐transcribed into single‐stranded 
cDNA using a High Capacity RNA‐to‐cDNA Kit (Life Technologies). The reverse transcription–
PCR was performed using the first‐strand cDNA with TaqMan Fast Universal PCR Master Mix 
(Life Technologies). Quantitative PCR was performed on a Quant Studio 6 Flex Real-Time PCR 
system (Applied Biosystems).   PCR parameters for cycling were as follows: +50°C incubation for 
2min, +95°C for 10min, 40 cycles of PCR at +95°C for 15sec, and +60°C for 1min. The following 
 by guest on January 26, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
 
 
Taqman assays were used: -Actin (Ss033376160_u1), U6 (Ubiquitin 6, 001973), and PPIA 
(Peptidyl-prolyl isomerase A Ss03394782_g1) as a housekeepers; for characterization of 
angiogenesis-related mRNAs and micro-RNAs: VEGF-A (Ss03393990_m1), TBX18 
(Hs01385457_m1), miR210 (3p CUGUGCGUGUGACAGCGGCUGA), and miR132 (3p 
UAACAGUCUACAGCCAUGGUCG); for lineage characterization and purity assessment: CD31 
(Ss03392600_u1), CD45 (Ss03376444_u1), CD11b (Ss03374590_m1). 
Differentiation of sAPCs 
For induction of osteogenesis, sAPCs were cultured in Dulbecco’s Modified Eagle medium 
(DMEM, Life Technology, UK) supplemented with L-ascorbic acid 2-phosphate (50µM), 
dexamethasone (0.1µM) and β-glycerol phosphate (10mM). For adipogenic differentiation cells 
were cultured in DMEM supplemented with dexamethasone (1µM), indomethacin (100µM), insulin 
(10µg/mL) and 3-isobutyl-1-methylxanthine (500µM). The media were replaced every three days. 
Network formation 
Swine or human APCs were stained with the long-term cell tracker VyBrant diL (Life 
Technologies, UK) and co-cultured with swine pulmonary artery endothelial cells (sPAECs) at a 
ratio 1:4 on Matrigel substrate (BD Biosciences, UK), containing Endothelial cell growth medium 
(EGM-2) and incubated for 6 hours. Each cell type was also seeded alone as control. In addition, 
to assess the effect of the secretome of the cells. sAPC and hAPC conditioned media (CM) diluted 
1:2 with fresh EGM-2 and swine serum, were incubated with sPAECs on Matrigel for 6 hours. 
Myocardial infarction procedure 
The MI protocol is detailed elsewhere.1, 2 Anesthesia was induced by intramuscular injection of 
ketamine (20 mg/kg), xylazine (2 mg/kg), and midazolam (0.5 mg/kg), and maintained by 
continuous intravenous infusion of ketamine (2 mg/kg/h), xylazine (0.2 mg/kg/h), and midazolam 
(0.2 mg/kg/h). Animals were intubated and mechanically ventilated with oxygen (fraction of 
inspired O2: 28%). Central venous and arterial lines were inserted, and a single bolus of 
unfractioned heparin (300 IU/kg) was administered at the onset of instrumentation. The left 
anterior descending coronary artery, immediately distal to the origin of the first diagonal branch, 
was occluded for 50min with an angioplasty balloon introduced via the percutaneous femoral 
route using the Seldinger technique. Balloon location and maintenance of inflation were monitored 
angiographically. After balloon deflation, a coronary angiogram was recorded to confirm patency 
of the coronary artery. A continuous infusion of amiodarone (300 mg/h) was maintained during 
the procedure in all swine to prevent malignant ventricular arrhythmias. In cases of ventricular 
fibrillation, a biphasic defibrillator was used to deliver non-synchronized shocks.  
CMR protocol 
Baseline CMR scans were performed at day 5 post-MI immediately before randomization to 
vehicle or APC intra-myocardial injection, and subsequent follow-up CMR scans were performed 
at day 45 post-MI. All CMR examinations were conducted with a Philips 3-Tesla Achieva Tx whole 
body scanner (Philips Healthcare, Best, the Netherlands) equipped with a 32-element phased-
array cardiac coil. The imaging protocol included The protocol included a standard segmented 
cine steady-state free-precession (SSFP) sequence to provide high-quality anatomical 
references, and to determine left-ventricle end-diastolic wall thickness, end-diastolic volume 
(LVEDV), end-systolic volume (LVESV) and left ventricular ejection fraction (LVEF);3 a dynamic 
acquisition with dual-saturation technique during gadolinium-based contrast administration to 
determine absolute myocardial perfusion;4 and a late gadolinium-enhanced (LGE) sequence to 
assess infarct size.3  
All sequences were acquired in free-breathing mode. The imaging parameters for the 
SSFP sequence were FOV 280 x 280 mm, slice thickness 6 mm with no gap, TR 2.8 ms, TE 1.4 
ms, flip angle 45°, cardiac phases 30, voxel size 1.8 x 1.8 mm, and 3 NEX. The first-pass perfusion 
was acquired by dynamic dual saturation-recovery gradient echo in 3 short-axis slices at the 
basal, mid-ventricular and apical level (TS=100ms). An extra slice was interleaved at the level of 
aorta output track to measure the vascular input function in the coronary with a shorter saturation 
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time (TS=20ms). All other parameters were equivalents between both acquisitions (slice 
thickness 6, gap 8, TR/TE: 2.6/1.3, Flip angle: 15°, FOV 280x300, Bandwidth: 460, SENSE factor 
=2). Before contras injection T1 mapping MOLLI sequence was acquired at the same levels to 
improve the accuracy to convert from signal intensity to contrast concentration. All animals 
received an intravenous dose of 0.1 mmol/Kg of gadolinium at 3 mL/s for first-pass perfusion 
imaging and an additional dose of 0.1 mmol/Kg of gadolinium at 3 mL/s for LGE imaging. Thus, 
LGE imaging was performed 10 to 15min after intravenous administration of 0.20 mmol of 
gadopentetate dimeglumine contrast agent per kg of body weight using a T1 inversion-recovery 
spoiled turbo field echo (T1-IR-TFE) sequence with the following parameters: FOV 280 × 280 
mm, voxel size 1.6 × 1.6 mm, end-diastolic acquisition, thickness 6 mm with no gap, TR 5.6 ms, 
TE 2.8 ms, inversion delay time optimized to null normal myocardium, and 2 NEX. 
SSFP and T1-IR-TFE sequences were performed to acquire 13 to 15 contiguous short-
axis slices covering the heart from the base to the apex, whereas perfusion imaging was analyzed 
in a mid-apical ventricular short axis slice.  
CMR analysis 
CMR images were analyzed using dedicated software (MR Extended Work Space 2.6, Philips 
Healthcare, The Netherlands; and QMassMR 7.6, Medis, Leiden, The Netherlands) by two 
observers experienced in CMR analysis and blinded to treatment allocation. LV mass and ejection 
fraction, myocardial perfusion and extent of necrosis were determined. 
LV cardiac borders were automatically traced with manual adjustment in each cine image 
to assess the LVEDV, LVESV, and LVEF. In the tracing convention used, the papillary muscles 
were included as part of the LV cavity volume. Ejection fraction (EF) was computed as EF= 
(LVEDV-LVESV)/LVEDV. LV epicardial borders were also traced on the end-diastolic images, 
with LV mass computed as the end-diastolic myocardial volume (i.e., the difference between the 
epicardial and endocardial volumes) multiplied by myocardial density (1.05 g/mL). Values of LV 
mass normalized to body surface area were calculated with modified Brody’s formula.5 
Before perfusion analysis, time intensity curves were transformed to contrast 
concentration using T1 values information. After contrast conversion, absolute flow values were 
obtained by pharmacokinetic signal modelling using the vascular input function and the swine 
hematocrit as correction factors. Myocardial perfusion expressed as mL/100g/min. On the 
absolute flow map regions of interest (ROI) of 0.5 cm2 were manually drawn in a mid-ventricular 
slice at the core infarcted area, infarct borders and at the remote myocardium with special care 
not to include a ventricular cavity. 
Myocardial necrosis (infarct size, IS), expressed as a percentage of LV mass, was defined 
according to the extent of late gadolinium enhancement after manually tracing the endocardial 
and epicardial contours on T1-IR-TFE short axis images. Abnormal areas were defined using the 
full-width at half-maximum, with manual correction if needed. Hypo-intense black areas within the 
necrotic zone, corresponding to microvascular obstruction, were included within the necrotic 
area.6, 7  
Intramyocardial injection of vehicle and APCs 
Injections in the peri-infarct zones of the LV was carried out via a left anterior mini-thoracotomy 
under general anaesthesia by an expert cardiac surgeon blind to the treatment allocation. 
Sedation was maintained with sevoflurane. Continuous intravenous infusion of fentanyl served as 
an analgesic during surgery, and a single dose of prophylactic antibiotic with cefuroxime was 
administered just before the procedure. Mechanical endotracheal ventilation was controlled by an 
external respirator.  
A minimally invasive right lateral thoracotomy was then performed in the third intercostal 
space as previously described.8, 9 Then, left internal mammary artery was dissected and ligated 
for a better visualization of peri-infarcted areas. Through a small peri-cardiotomy, the anterior and 
lateral LV walls were exposed, and a total of N=10 micro-injections (for a total volume ~3mL) were 
performed at the peri-infarct zones under direct vision. After administration was finished, the small 
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peri-cardiotomy was left open, the chest wall and skin incisions were closed and the 
pneumothorax was evacuated with a chest tube. Animals were extubated and sent to the recovery 
room.  After surgery and before the animals recovered from anesthesia, intramuscular (0.01 
mg/kg) buprenorphine was administered as a postoperative analgesia. During their recuperation, 
animals were cared for by dedicated veterinarians and technicians at the CNIC. All animals were 
returned to the farm before final follow-up CMR and sacrifice. 
Collection and analyses of swine hearts  
At sacrifice, animals were subjected to an overdose of anesthetic (ketamine, xylazine and 
midazolam) to collect hearts and perform histological analyses.  
Samples processing for histology 
After explantation of the porcine hearts, 4 different areas of the LV (Remote= REM, Peri-Infarct 
Anterior= PIA, Peri-Infarct Inferior= PII and Infarct= INF) were collected and washed once in 1x 
PBS prior to fixation with freshly prepared 4% (w/v) PFA (Sigma-Aldrich, 441244) in PBS for 48 
hours at 4°C. After the fixation, heart samples were washed once with 1x PBS and included in 
paraffin and sectioned at a thickness of 5 μm for subsequent immunohistochemistry analysis. 
Vascular density  
For capillary density, paraffin sections were incubated with biotinylated Isolectin B4 diluted 1:200 
(Life Technologies, I21414 ) overnight in a humidified chamber and at +4°C, followed by the 
incubation of streptavidin Alexa Fluor 488 diluted 1:200 (Life Technologies, S11223) 1h at RT. 
For arteriole density, the same sections were probed with α-Smooth Muscle Actin (α-SMA) 
antibody conjugated with Cy3 diluted 1:400 (Sigma-Aldrich, C6198) 1h at RT. Capillaries and 
arterioles were calculated in 40 fields (at X200 magnification) in the Peri-Infarct myocardium, and 
the final data expressed as the number of capillaries or arterioles per square millimeter. The 
analysis was performed using the free software ImageJ (http://imagej.nih.gov/ij/). Adobe 
Photoshop software was utilized to compose and overlay the images (Adobe). 
Interstitial Fibrosis  
Peri-Infarct paraffin sections were stained with Masson's trichrome stain for cardiac fibrosis 
quantification. Then, 20 pictures at X200 magnification were taken from each section for the 
subsequent fibrosis analysis with Image J software. The final data was expressed as the 
percentage of the fibrotic area from the total quantified area. 
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Table S1. Antibodies used in immunocytochemistry studies of sAPCs 
Marker Technique Permeabilization Reactivity Primary antibody 
source and dilution 
Secondary antibody 
source 
NG2 ICC Yes Swine NovusBiological, 1:50 Invitrogen, A488 Goat α-Rabbit 
PDGFRβ ICC Yes Swine GeneTex, 1:100 Invitrogen, A488 Goat α-Mouse 
CD34 ICC Yes Swine GeneTex, 1:50 Invitrogen, A488 Goat α-Mouse 
Vimentin ICC Yes Human Abcam, 1:400 Invitrogen, A488 Goat α-Rabbit 
SOX2 ICC Yes Human/Swine Merck Millipore, 1:100 Invitrogen, A488 Goat α-Rabbit 
GATA-4 ICC Yes Human Abcam, 1:100 Invitrogen, A488 Goat α-rabbit 
OCT-4 ICC Yes Human/Swine Abcam, 1:100 Invitrogen, A488 Goat α-Rabbit 
CD31 ICC Yes Swine Abcam, 1:20 Invitrogen, A488 Goat α-Rabbit 
VE-cadherin ICC Yes Human/Swine Santa Cruz, 1:50 Invitrogen, A488 Goat α-Mouse 
CD146 ICC Yes Human/Swine Abcam, 1:100 Invitrogen, A488 Goat α-Rabbit 
Biotinylated 
Isolectin-B4 
IHC Yes Human/Swine Invitrogen; 1:200 Invitrogen, A488 Streptavidin  
α-SMA-Cy3 IHC Yes Human/Swine Invitrogen; 1:100  
WGA-A488 IHC Yes Human/Swine Invitrogen; 1:100  
α-SA IHC Yes Human/Swine Sigma; 1:200 Invitrogen, 649 Donkey-α mouse 
IgM 
VEGF-A WB N/A Human/Swine Antibodies-Online; 
1:200 
GE Healthcare; ECL Donkey α-
Rabbit IgG-HRP, 1:5000 
TBX18 WB N/A Human Santa Cruz; 1:400 GE Healthcare; ECL Sheep α-
Mouse IgG-HRP, 1:5000 
β-actin WB N/A Human/Swine Sigma; 1:30000 GE/Healthcare; ECL Sheep α-
Mouse IgG-HRP, 1:5000 
 
Cells (N=4 biological replicates run in triplicate) were fixed with freshly prepared 4% (W/V) PFA in PBS for 10min at +4°C , washed 
with PBS and probed with the indicated antibodies. For detection of intracellular antigens, cells were permeabilized for 10min at +4°C 
with 0.3% (v/v) Triton X-100 (Sigma-Aldrich) diluted in PBS. Cells were incubated with the indicated primary antibodies (16h at +4°C) 
and appropriate secondary antibodies (1:200 anti-rabbit Alexa 488 or 1:200 anti-mouse Alexa 488, 1h at +20°C in the dark). The 
nuclei were counterstained with DAPI (Sigma-Aldrich). Slides were mounted using Fluoromount-G (Sigma-Aldrich). Cells were 
analyzed at a 200X and 400X magnification. The PhotoPlus X6 software was utilized to compose and overlay the images (Adobe). 
Swine Pulmonary Artery Endothelial Cells (sPAECs, AMSBio, USA) at P4 were used as positive controls.  
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Table S2. Antibodies used in flow cytometry studies on sAPCs 
Marker Permeabilization Reactivity Primary antibody 
source dilution 
Fluorophores 
CD90 No Swine eBioscience, 1:20 Pe-Cy7 
CD44 No Swine eBioscience, 1:20 APC 
CD105 No Swine LifeSpan, 1:5 PE 
CD45 No Swine Serotec, 1:25 FITC 
CD11b No Human/Swine eBioscience, 1:20 Pe-Cy7 
CD31 No Swine Serotec, 1:80 PE 
CD146 No Swine Serotec, 1:60 FITC 
PDGFR No Human Biolegend, 1:25 PE 
Dye eFluor 780 No  eBioscience, 1:1000  APC-Cy7 
 
Cells (1x106, N=3 biological replicates) were washed in 1X DPBS (Life Technologies) and treated with 10X trypsin/EDTA (Life 
Technologies). Then, cells were washed, spun at 400xg for 10min at 4°C and re-suspended in FACS-staining buffer containing 0.1% 
(v/v) BSA, 1mM EDTA and 0.1% (W/V) sodium azide, followed by blocking of unspecific binding with 10% (v/v) BSA in 1X DPBS. 
2x105 cells/tube were incubated with mesenchymal and hematopoietic antibodies for 30min, at +4°C, in the dark). For endothelial 
marker CD31, cells were incubated for 15min, on ice in the dark, followed by three washes in 1X DPBS. Fixable Viability Dye eFluor 
780 (ebioscience, UK) was used for the exclusion of dead cells from the gating procedure.  A single fixation with 1% (W/V) PFA was 
applied after the staining instead of a double fixation protocol routinely used in the hAPC-SOP. Swine PB-MNCs and PAECs were 
employed as a positive control for hematopoietic and endothelial markers, respectively.  
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Table S3. Taqman probes used in the molecular biology studies of sAPCs. 
Gene Species Assay ID 
PPIA (housekeeper) Swine Ss03394782_g1 
-Actin (housekeeper) Swine Ss033376160_u1 
UBC (housekeeper) Human Hs00824723_m1 
U6 snRNA 
(housekeeper) 
Human 001973 
Cel-miR-39 
(spike-in control) 
C. Elegans Cel-miR-39-3p 
VEGF-A (target) Swine Ss0339390_m1 
miR-132 (target) Human/Swine Hsa-miR-132-3p 
miR-210 (target) Human/Swine Hsa-miR-210-3p 
CD31 (target) Swine Ss03392600_u1 
CD45 (target) Swine Ss03376444_u1 
CD11b (target) Swine Ss03374590_m1 
Tbx-18 (target) Human Hs01385457_m1 
 
Total RNA was obtained from cultured APCs (miRNeasy mini kit, Cat n#: 217004, Qiagen) and reverse‐transcribed using a High 
Capacity RNA‐to‐cDNA Kit (Cat n#: 4387406, Life Technologies), and TaqMan MicroRNA Reverse Transcription Kit (Cat n#: 4366596, 
Applied biosystem). The reverse transcription–PCR was performed using the first‐strand cDNA with TaqMan Fast Universal PCR 
Master Mix (Cat n#:  4324018, Life Technologies) and on a Quant Studio 6 Flex Real-Time PCR system (Applied Biosystems) for the 
genes specified above (Table). 
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Figure S1. Genetic analysis of expanded hAPCs. 
 
 
 
 
Chromosome analysis was successful in three out of five hAPC lines. Two showed a normal karyotype, while the third showed a 
balanced rearrangement at P2 (A) and an unrelated unbalanced rearrangement at P7 (B). Abbreviations: hAPC = human Adventitial 
Progenitor Cells. 
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Figure S2. Mesenchymal differentiation of sAPCs. 
 
 
 
Representative images showing the differentiation capacities of sAPCs towards mesodermal lineages. Lipid droplets were identified 
by Oil Red staining (red) (A) and calcium deposits by Alizarin red (B) and ALP staining (C) in two sAPC lines. Magnification 100x. 
Inserts show details of the positive staining. In A, sAPCs maintained under normal culture medium are also shown (Negative control). 
Abbreviations: ALP = Alkaline Phosphatase; sAPC = swine Adventitial Progenitor Cells. 
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Figure S3. Cytotoxic activity of sAPCs and swine splenocytes in suspension. 
 
 
 
 
 
To investigate cell-mediated toxicity, sAPCs (target cells) were incubated alone or with activated swine splenocytes (effector cells). 
Bar graph showing the percentage of viable (Annexin V-/P.I.-), early apoptotic (Annexin V+/P.I.-), late apoptotic (Annexin V+/P.I.+), and 
necrotic (Annexin V-/P.I.+) sAPCs. There was a spontaneous, time-dependent activation of cytotoxicity when sAPCs were maintained 
alone in suspension for more than 1h. However, incubation of sAPCs with swine splenocytes for 4h in suspension did not further 
increase the cytotoxic response. Data are expressed as mean±SEM; N=3 biological replicates. *P<0.05 and **P<0.01 vs. time 0. 
Abbreviations: P.I. = Propidium Iodide; sAPC = swine Adventitial Progenitor Cells. 
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Supplemental Video Legends 
 
Videos show representative CMR imaging of the hearts at 5 and 45 days after myocardial 
infarction induction.  
 
Videos S1-2: Vehicle-injected swine (ID# 2644) with CMR imaging captured at 5 day (1) or 45 
day post-MI (2). Format: Windows Media Video file (WMV). 
 
Videos S3-4: hAPC-injected swine (ID#2647) with CMR imaging captured at 5 day (3) or 45 
day post-MI (4). Format: Windows Media Video file (WMV). 
 
Videos S5-6: Vehicle-injected swine (ID#4146) with CMR imaging captured at 5 day (5) or 45 
day post-MI (6). Format: Windows Media Video file (WMV). 
 
Videos S7-8: sAPC-injected swine (ID#4126) with CMR imaging captured at 5 day (7) or 45 
day post-MI (8). Format: Windows Media Video file (WMV). 
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